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Nonalcoholic steatohepatitis (NASH) is defined as abnormal lipid accumulation in 
the liver and subsequent liver injury, inflammation and fibrosis, which is 
concerned with obesity, insulin resistance and other metabolic disorders and 
sometimes progresses to liver cirrhosis and hepatocellular carcinoma. However, 
the molecular mechanism of the onset and progression of NASH is poorly 
understood. In order to elucidate the molecular mechanism, I focused on two 
crucial processes in NASH pathology, the onset process and the progression of 
liver fibrosis. 
 Stearoyl-CoA desaturase-1 (SCD-1) catalyzes the biosynthesis of 
monounsaturated fatty acids from saturated fatty acids and regulates triglyceride 
synthesis. The abnormality of SCD-1 seems to be responsible for obesity, insulin 
resistance, and hepatic steatosis. In order to elucidate the effects of SCD-1 on the 
onset of NASH, an SCD-1 inhibitor was administered to rats fed with methionine 
and choline-deficient (MCD) diets for 8 weeks, which showed hepatic steatosis, 
liver injury, inflammation and early fibrosis. Administration of the SCD-1 
inhibitor decreased triglyceride accumulation in the liver of MCD rats. 
Administration of the SCD-1 inhibitor also attenuated the increase of plasma AST 
and ALT. Hepatic steatosis, hepatocellular degeneration, inflammatory cell 
infiltration and early fibrosis were histologically observed in liver of MCD rats, 
and administration of the SCD-1 inhibitor ameliorated these crucial problems in 
NASH. These results suggest that the SCD-1 inhibitor prevented hepatic steatosis 
and decreased sensitivity to the onset of the NASH phenotype including liver 
injury, inflammation and fibrosis.  
 Angiotensin II (Ang II), a major component of renin-angiotensin systems, 
possibly plays an important role in the pathogenesis of liver fibrosis which is the 
most crucial phenotype in chronic liver disease including NASH. In order to 
elucidate the effects of Ang II on the progression of liver fibrosis, an Ang II type 1 
receptor blocker (ARB) was administered to rats that received bile duct ligation 
(BDL), which are liver fibrosis models without hepatic steatosis. ARB treatment 
inhibited the accumulation of liver collagen. Activated hepatic stellate cells 
(HSCs), key players in liver fibrogenesis, were highly accumulated in the area of 
collagen deposition in the livers of BDL rats. Furthermore, these cells expressed 
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AT1 receptors. ARB treatment decreased the accumulation of SMA expressing 
AT1 receptors as well as collagen deposition. The effects of Ang II on fibrogenic 
phenotypes in in vitro activated HSCs were also evaluated. Ang II stimulated 
proliferation and collagen synthesis in activated HSCs and ARB treatment 
completely blocked them. Additionally, pro-fibrogenic cytokines, transforming 
growth factor-1 and connective tissue growth factor were up-regulated by Ang II 
stimulation through AT1 receptors, suggesting their involvement to 
Ang II-stimulated activation of HSCs. These results suggest that Ang II stimulates 
the key phenotypes of activated HSCs through activation of AT1 receptors and 
consequently leads to the development of liver fibrosis 
 In conclusion, I demonstrated that SCD-1 and Ang II plays key roles in the 
onset process and the progression of liver fibrosis in NASH, respectively. 
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Abbreviations 
 
 
ACE: angiotensin-converting enzyme 
-SMA: -smooth muscle actin 
ALT: alanine aminotransferase 
Ang II: angiotensin II 
ARB: angiotensin receptor blocker 
AST: aspartate aminotransferase 
AT1: angiotensin II type 1 
AT2: angiotensin II type 2 
BDL: bile duct ligation 
ChREBP: carbohydrate response element-binding protein 
CMC: carboxymethyl cellulose 
Col1a1-Luc Tg: rat collagen 1a1 promoter-luciferase transgenic 
CTGF: connective tissue growth factor 
DAB: 3,3’-diaminobenzidine tetrahydrochloride 
DMEM: Dulbecco’s modified Eagle medium 
ECM: extracellular matrix 
FCS: fetal calf serum 
FFA: free fatty acid 
GBSS: Gey’s balanced salts solution 
HBSS: Hanks’ balanced salts solution 
HSC: hepatic stellate cell 
LXR: liver X receptor 
MCD: methionine and choline-deficient 
MCP-1: monocyte chemotactic protein-1 
MUFA: monounsaturated fatty acid 
NAFLD: nonalcoholic fatty liver disease 
NASH: nonalcoholic steatohepatitis 
Olmesartan: olmesartan medoxomil 
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PBS: phosphate-buffered saline 
PDGF: platelet-derived growth factor 
PG:Tween: polyethylene glycol: Tween 80 
RAS: renin-angiotensin system 
SCD: stearoyl-CoA desaturase 
SD: Sprague-Dawley 
SREBP-1c: sterol regulatory element-binding protein-1c 
TBS: tris buffered-saline 
TCA: trichloroacetic acid 
TGF-1: transforming growth factor-1 
TIMP: tissue inhibitor of metalloproteinase 
VLDL: very low density lipoprotein 
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Nonalcoholic fatty liver disease (NAFLD), which is identified by excess lipid 
accumulation in the liver, is strongly associated with obesity, insulin resistance, 
type 2 diabetes, hypertension, dyslipidemia and metabolic syndrome (Farrell and 
Larter, 2006; Torres and Harrison, 2008). NAFLD is frequently observed in 
patients with metabolic disorders and about 10% of them progresses to 
nonalcoholic steatohepatitis (NASH), which shows histological observation of 
hepatocellular degeneration, inflammation and fibrosis in the liver in addition to 
steatosis. Some of NASH patients progress to liver cirrhosis and subsequently 
hepatocellular carcinomas, which are the end-stage of liver disease (Younossi et 
al., 2002). The population of NASH/NAFLD patients in advanced countries is 
increasing with the rise in obesity. Some clinical pilot studies have been performed 
with agents including insulin sensitizers, anti-dyslipidemic drugs, anti-obesity 
drugs and antioxidants (Marchesini et al., 2001; Harrison et al., 2003a, 2003b; 
Belfort et al., 2006; Gomez-Dominguez et al., 2006; Satapathy et al., 2006; Sanyal 
et al., 2010). Nevertheless, there is no established therapy for NASH/NAFLD at 
present (Malinowski et al., 2013).  
 The molecular mechanism of NASH/NAFLD remains poorly understood 
due to difficulties in elucidating the pathology. First, a liver biopsy is necessary to 
diagnose NASH and analyze the pathology in detail. Liver biopsy is highly 
invasive and has a high risk for complications such as bleeding and rare death. It is 
not realistic to repeatedly perform biopsies to observe the progression of the 
disease. Therefore, it is sometimes difficult to identify NASH patients particularly 
in early stages which are generally non-symptomatic. Although many researchers 
have tried to discover non-invasive biomarkers for NASH, there are no clinically 
validated biomarkers at present (Festi et al., 2013). Second, the background of 
metabolic disorders in NASH/NAFLD patients was very complicated. A lot of 
metabolic factors are dysregulated and the abnormal phenotypes are different 
among each patient. Therefore, it is hard to understand and find causative factors 
for NASH. 
 The “two hit theory” has been proposed for the mechanism of NASH onset 
and progression (Figure 1; page 76) (Day, 1998). The “first hit” is the lipid 
accumulation in the liver, which is caused by obesity, insulin resistance and other 
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metabolic disorders. Then, the “second hit” stimuli leads to liver injury, 
inflammation and finally fibrosis. Levels of fatty acids in liver are regulated by 
some processes including fatty acid uptake into liver, de novo fatty acid synthesis 
(lipogenesis), secretion from liver as very low density lipoprotein (VLDL) and 
fatty acid oxidation (Figure 2; page 77). In human obesity, the main mechanisms 
of lipid accumulation in liver are possibly due to increased fatty acid uptake and 
de novo lipogenesis caused by insulin resistance (Lewis et al., 2002). Plasma free 
fatty acids (FFAs) are mainly derived from adipose tissue and are released to 
plasma by the lipolysis of triglycerides in adipocytes. Insulin negatively regulates 
the lipolysis in adipocytes. Therefore, obesity-associated insulin resistance 
activates lipolysis and then plasma FFA levels are elevated. The expression of 
CD36 which regulates fatty acid uptake in the liver is also up-regulated in the liver 
of NAFLD patients (Greco et al., 2008). Increased plasma levels and liver uptake 
of FFAs lead to an excess influx and accumulation of FFAs in NAFLD liver. 
Furthermore, hyperglycemia and hyperinsulinemia resulting from insulin 
resistance can activate transcriptional factors regulating fatty acid synthesis in the 
liver including sterol regulatory element-binding protein (SREBP)-1c and 
carbohydrate response element-binding protein (ChREBP). In this manner, the 
increase of de novo lipogenesis may also cause lipid accumulation in NAFLD 
livers. Donnelly et al. has reported that 26% of liver triglyceride in NAFLD 
patients is derived from de novo lipogenesis compared with 5% in healthy persons 
(Donnelly et al., 2005). One important aspect of the two-hit theory is that steatosis 
per se is not causal in the development of NASH, but it sensitizes the liver to 
various second hit stimuli. Some factors such as oxidative stress, endotoxin and 
other bacterial components and inflammatory cytokines have been proposed as the 
second hits. However, the precise molecular mechanism is poorly understood. 
 Chronic injury and continuous inflammation in the liver lead to liver 
fibrosis and the progression of fibrosis finally causes cirrhosis and hepatocellular 
carcinoma, which are often lethal. Liver fibrosis is the predominant and most 
harmful process in NASH and is characterized by the abnormal accumulation of an 
extracellular matrix (ECM) such as collagen (Hernandez-Gea and Friedman, 2011). 
Fibrosis is generally observed in various chronic liver diseases including NASH. 
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Hepatic stellate cells (HSCs) are a major source of ECM in the liver, and HSCs 
account for approximately 5% to 8% of total cells in normal livers (Friedman, 
2008). HSCs possess vitamin A droplets and produce small amounts of ECM 
components in normal conditions, which are called “quiescent HSCs.” In injured 
livers, HSCs morphologically transform to myofibroblast-like cells, characterized 
as having a proliferative, fibrogenic and contractile phenotype. Their transformed 
cells express -smooth muscle actin (-SMA), which are called “activated HSCs.” 
Activated HSCs can produce an excess of collagen and other ECM components 
and simultaneously inhibit ECM degradation by the induction of tissue inhibitor of 
metalloproteinases (TIMPs), resulting in ECM accumulation in the liver. In injured 
liver, some factors, which are produced from surrounding cells such as 
hepatocytes, Kupffer cells, sinusoidal endothelial cells and inflammatory cells, are 
thought to activate HSCs in a paracrine manner although the precise mechanism is 
poorly understood (Friedman, 2008). Transforming growth factor-1 (TGF-1) 
plays an important role in the activation of HSCs. TGF-1 mainly stimulates the 
activation and collagen synthesis of HSCs in an autocrine or paracrine manner 
(Matsuoka and Tsukamoto, 1990; Gressner, 1995). It has been reported that a 
blockade of TGF-1 by the injection of a soluble type or dominant-negative type 
of TGF-1 type II receptors into animals, prevented experimental liver fibrosis 
(George et al., 1999; Qi et al., 1999; Yata et al., 2002). Thus, TGF-1 is highly 
involved in the pathogenesis of liver fibrosis. Connective tissue growth factor 
(CTGF), a cysteine-rich protein that belongs to the family of CNN, is thought to 
act as a downstream mediator of the fibrogenic actions of TGF-1, and also plays 
an important role in the development of fibrosis in a variety of organs (Leask et al., 
2002). It was reported that CTGF mRNA was up-regulated in human liver 
cirrhosis or activated HSCs, and recombinant CTGF stimulated activation of HSCs 
(Paradis et al., 1999, 2002; Williams et al., 2000). In this manner, these two 
cytokines are thought to be highly concerned with activation of HSCs. 
 In my present study, in order to elucidate the molecular mechanism of 
NASH, I focused on two crucial processes, the onset of NASH and progression of 
fibrosis. I focused on stearoyl-CoA desaturase-1 (SCD-1) in the onset of NASH 
and angiotensin II (Ang II) in the progression of fibrosis as key factors. 
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Introduction 
 
 
SCD is an endoplasmic reticulum enzyme that catalyzes the biosynthesis of 
monounsaturated fatty acids (MUFAs) from saturated fatty acyl-CoAs (Ntambi, 
1995). SCD, in conjunction with the NADPH, the flavoprotein cytochrome b5 
reductase, and the electron acceptor cytochrome b5, introduces the cis double 
bond in the 9 position of fatty acyl-CoA substrates, preferentially stearoyl 
(C18:0) and palmitoyl (C16:0)-CoA. These MUFAs are used as substrates for the 
synthesis of triglycerides, cholesteryl esters, membrane phospholipids, and wax 
esters. Two human and four mouse SCD isoforms have been characterized (Ntambi, 
1995). Some studies have indicated that SCD-1 is the main isoform and plays a 
central role in regulation of fatty acid and triglyceride composition in the liver 
(Miyazaki et al., 2000). Dietary carbohydrates can induce SCD-1 and lipogenic 
genes in the liver (Sampath and Ntambi, 2011). First, increased insulin secretion 
by dietary carbohydrate induces lipogenic transcription factors, sterol regulatory 
element binding protein 1c (SREBP-1c) and liver X receptor (LXR), which can 
activate transcription of SCD-1 and other lipogenic genes (Chen et al., 2004). 
Second, increased influx of glucose or fructose to liver can also induce SCD-1 and 
other lipogenic genes by a SREBP-1c-dependent and -independent mechanism 
(Miyazaki et al., 2001a, 2004). Therefore, the excess intake of dietary 
carbohydrate and some kind of fatty acids, or a food condition that increases 
insulin secretion possibly causes increased liver SCD-1 activity and triglyceride 
accumulation. 
 SCD-1 deficiency in the whole body or liver has reduced lipid synthesis 
and enhanced lipid oxidation, thermogenesis and insulin sensitivity in various 
tissues including liver, muscle and adipose tissue. These metabolic changes protect 
SCD-1-deficient mice against a variety of dietary, pharmacological and genetic 
conditions that promote obesity, insulin resistance and hepatic steatosis (Ntambi et 
al., 2002; Rahman et al., 2003, 2005; Miyazaki et al., 2007). Additionally, 
pharmacological inhibition of SCD-1 also improved hepatic lipid accumulation 
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and metabolic disorders (Issandou et al., 2009; Koltun et al., 2009; Ramtohul et al., 
2010). These reports demonstrate that SCD-1 plays a key role in regulating hepatic 
triglyceride levels and abnormal activation of SCD-1 may lead to hepatic steatosis. 
In contrast, it is poorly understood how SCD-1 affects the onset of the NASH 
phenotype including liver injury, inflammation and fibrosis. In this chapter, I 
evaluated the effects of SCD-1 on onset phase of NASH in rat models using an 
SCD-1 inhibitor. 
 Many animal models have been used for NASH/NAFLD research. Obese 
and type 2 diabetes models such as ob/ob mice, db/db mice and Zucker fatty rats 
generally do not lead to liver fibrosis; therefore they are not useful in researching 
NASH pathology. Actually, some of the NASH/NAFLD models exhibit no or 
slight fibrosis. Methionine and choline-deficient (MCD) diet models are one of the 
most useful NASH models and they develop liver fibrosis that is histologically 
similar to human NASH (Fan and Qiao, 2009). Methionine and choline are used to 
synthesize phosphatidylcholine, which is necessary for the secretion of 
triglyceride from the liver to blood as VLDL. Consequently, deficiency in 
methionine and choline leads to triglyceride accumulation in the liver. 
Additionally, methionine is a precursor of glutathione, an endogenous 
antioxidative protein. Deficiency in methionine also causes oxidative stress in 
liver and subsequently leads to liver injury, inflammation and fibrosis. However, 
MCD diet models require a long time period (over 3 or 4 months) to exhibit 
remarkable fibrosis. For efficient in vivo screening of drug candidates, the 
throughput was very important. Therefore, I tried to modify the MCD models to 
evaluate fibrosis in a shorter period than conventional methods. It has been 
reported that rat collagen 1a1 promoter-luciferase transgenic (Col1a1-Luc Tg) rats, 
in which the expression of luciferase is regulated under the native promoter of 
collagen 1a1, were established. They are appropriate to sensitively evaluate the 
fibrosis of kidneys and various organs in a short-term period (Terashima et al., 
2010). In these rats, the pro-fibrogenic response with altered mRNA expression of 
collagen 1a1 could be detected even if protein levels of collagen are not 
sufficiently increased. Furthermore, luciferase is easier to measure than real time 
RT-PCR analysis; therefore they are useful in in vivo screening. In my present 
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study, Col1a1-Luc Tg rats were used to evaluate the effects of SCD-1 on the onset 
of NASH including the pro-fibrogenic response in a short-term period. 
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Materials and Methods 
 
 
Synthesis of an SCD-1 inhibitor 
N-(2-hydroxy-2-phenylethyl)-6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-
carboxamide (Figure 3; page 78), a potent and orally available SCD-1 inhibitor 
named as compound A, was discovered by Daiichi Sankyo, Co., Ltd. The detailed 
synthetic procedures, physicochemical properties and pharmacokinetic profile of 
compound A with this structural motif have been previously reported (Uto et al., 
2010). 
 
Animals 
All experimental procedures were performed in accordance with the in-house 
guideline of the International Animal Care and Use Committee of Daiichi Sankyo 
Co., Ltd. Col1a1-Luc Tg rats were generated by a previously reported method, and 
bred in Japan SLC Inc. (Shizuoka, Japan) (Terashima et al., 2010). C57BL/6J mice 
were purchased from Charles River Laboratories Japan, Inc. (Yokohama, Japan). 
They were maintained in a room under a temperature controlled at 23°C±2 and a 
12-hour light-dark lighting cycle. The animals were allowed a standard pellet 
chow before the experiment and water ad libitum. Anesthesia was performed by 
intraperitoneally injecting pentobarbital (Dainippon Pharmaceutical, Osaka, 
Japan) at a dose of 50 mg/kg. 
 
Mice fed with lipogenic diets 
In order to evaluate liver SCD-1 activity, 9 week old male C57BL/6J mice were 
fed with non-fat and high-sucrose (lipogenic) diets (Research Diets, Inc., New 
Brunswich, NJ, USA, ) for 7 days prior to administration of compound A. 
Lipogenic diets were composed of 22 kcal% protein and 78 kcal% carbohydrate as 
sucrose. Compound A was administered once at doses of 10, 30 and 100 mg/kg 
(n = 2) to mice by oral gavage in a 4:1 mixture of polypyleneglycol and Tween 80 
(PG:Tween) as vehicle. In order to evaluate liver triglyceride content, the mice 
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were fed with lipogenic diets for 14 days, and compound A was administered 
once-daily at doses of 10, 30 and 100 mg/kg (n = 6) to mice during the last 7 days 
of the feeding of lipogenic diets. The mice in the normal group were fed with 
standard chow diets (FR-2, Funabashi Farm Co., Chiba, Japan). At the next day of 
the 7th administration of compound A, the mice were sacrificed and the livers 
were removed and washed with saline. The specimens of liver were immediately 
snap-frozen and stored at –80°C to measure triglyceride content. 
 
In vivo liver SCD-1 activity 
After 6 hours of administration of compound A in mice fed with lipogenic diets, 
[14C]stearate (Daiichi Pure Chemicals, Tokyo, Japan) dissolved in saline 
containing 2% bovine serum albumin was intraperitoneally administered at a dose 
of 100 L/kg to mice. One hour after the injection of [14C]stearate, the mice were 
sacrificed under anesthesia and the livers were collected and quickly frozen in 
liquid nitrogen. The livers were homogenized in 9×volume of cold phosphate 
buffered-saline (PBS), and 250 L of homogenates were mixed with an equal 
volume of methanol containing 10% KOH and then the mixture was saponified at 
80°C for 30 min. The free fatty acids in the reaction were protonated by the 
addition of 5N HCl (15 L) and extracted with 100 L ethyl acetate. The 30 L of 
the ethyl acetate extracts of each reaction were charged to an AgNO3-TLC plate 
(20 x 20 cm LK5D plates, 150 Å pore diameter, 250 m thick) and differentiated 
in a solvent consisting of chloroform : methanol : acetate : water (90:8:1:0.8). The 
[14C]stearate and [14C]oleate were quantified with BAS2500 (Fujifilm Corporation, 
Tokyo, Japan) and SCD-1 activity was determined as the ratio of [14C]oleate to 
[14C]stearate. 
 
Rats fed with MCD diets 
In the first experiments, male Col1a1-Luc Tg rats (184 to 247 g body weight) were 
randomly divided into four groups as follows: 
 Group 1: Control sacrificed at 2 weeks (n = 5) 
 Group 2: MCD sacrificed at 2 weeks (n = 5) 
 Group 3: Control sacrificed at 8 weeks (n = 5) 
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 Group 4: MCD sacrificed at 8 weeks (n = 5) 
Rats in Group 2 and 4 were fed with lipogenic MCD diets (Oriental Yeast Co., Ltd, 
Tokyo, Japan). Lipogenic MCD diets were composed of 16 kcal% protein (as 
defined amino acid), 63 kcal% carbohydrate (7:3 sucrose-corn starch) and 
21 kcal% fat (as corn oil). Rats in Group 1 and 3 were fed with lipogenic MCD 
diets supplemented with 3 g/kg of DL-methionine and 2 g/kg of choline bitarate. 
Rats were sacrificed under anesthesia at 2 weeks in Group 1 and 2, and 8 weeks in 
Group 3 and 4 after the beginning of the MCD diets, respectively. The livers were 
removed and washed with saline. The specimens of liver were immediately 
snap-frozen and stored at –80°C to measure liver lipid and luciferase content. 
 In the second experiments, male 16 weeks old Col1a1-Luc Tg rats (235 to 
282 g body weight) were randomly divided into four groups as follows: 
 Group 1: Control group (n = 4) 
 Group 2: MCD group (n = 8) 
 Group 3: Low dose of compound A group (n = 5) 
 Group 4: High dose of compound A group (n = 4) 
Rats in Group 2, 3 and 4 were fed with lipogenic MCD diets for 8 weeks. Rats in 
Group 1 were fed with lipogenic MCD diets supplemented with 3 g/kg of 
DL-methionine and 2 g/kg of choline bitartrate. Compound A dissolved in 
PG:Tween was administered once-daily at doses of 30 or 100 mg/kg by oral 
gavage to rats in Group 3 and Group 4 during the feeding of MCD diets, 
respectively. Rats in Group 1 and 2 were treated with PG:Tween as vehicle. Rats 
were sacrificed at 8 weeks after starting the administration under anesthesia. 
Blood was collected from the aorta, and plasma was separated by centrifugation 
and stored at −80°C. The livers were removed, washed with saline and weighed. 
The specimens of liver were immediately snap-frozen and stored at −80°C for 
TaqMan PCR analysis, measurement of liver lipid, luciferase and hydroxyproline 
content. Portions of the liver lobes were also fixed in 10% buffered formalin 
(Wako Pure Chemical Industries, Osaka, Japan) and embedded in paraffin for 
histopathological analysis. 
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Liver luciferase content 
The liver tissues were homogenized by a Polytron homogenizer (Kinematica AG, 
Luzen, Switzerland) with the addition of 1 mL PBS per 1 g of liver. After 
centrifugation at 3,000 rpm for 20 min, the luminescence in the supernatant was 
measured by a PicaGene kit (Toyo Ink MFG Co., Ltd., Tokyo, Japan). The 
concentration of luciferase was quantified using the standard curve of luciferase 
protein (Toyo Ink MFG Co.). The protein concentration was measured by a protein 
assay reagent (Bio-Rad Laboratories, Inc., Tokyo, Japan) , and luciferase was 
indicated as pg/mg protein. 
 
Liver triglyceride content 
A piece of liver was homogenized by Polytron homogenizer (Kinematica AG) with 
the addition of PBS. The homogenates were mixed with the combination of CHCl3 
and MeOH (2:1). After 5 minutes of combining by a vortex mixer, the solutions 
were centrifuged at 14,000 rpm for 3 min. The lower layers were collected and 
evaporated. After being dissolved in isopropanol containing 10% Triton, 
triglyceride content was measured by Triglyceride E test-Wako (Wako Pure 
Chemical Industries). 
 
Plasma AST and ALT 
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in 
the plasma were measured using an Autoanalyzer (Hitachi 7250, Hitachi 
High-Technologies Corporation, Tokyo, Japan). 
 
Real time RT-PCR analysis 
The liver tissues were homogenized by a Polytron homogenizer (Kinematica AG) 
with the addition of Trizol reagent (Invitrogen, Carlsbad, CA). After centrifugation 
at 10,000 rpm at 25°C, 0.2 mL chloroform was added and mixed by a vortex mixer. 
After 10 min incubation at room temperature, they were centrifuged at 10,000 rpm 
at 25°C, and the water layer was collected. RNA was purified by an Rneasy Mini 
Kit (Qiagen, Valencia, CA) and RNA concentration was measured by Gene Spec 
III (Hitachi, Tokyo, Japan). cDNA was synthesized by a High Capacity cDNA 
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Reverse Transcription Kit (Applied Biosystems, Foster City, CA). TaqMan PCR 
was carried out by ABI PRISM 7900 (PerkinElmer Life Sciences, Boston, MA). 
The mixture containing 5 L cDNA, 25 L TaqMan 2×PCR Master Mix (Applied 
Biosystems), 0.5 L forward primer, 0.5 L reverse primer and 0.5 L TaqMan 
probe, were reacted together. The thermal cycler conditions were 2 min at 50°C, 
10 min at 95°C, and 40 cycles of 15 sec at 95°C followed by 1 min at 60°C. The 
fluorescent TaqMan probes and forward and reverse primers were designed with 
the software Primer ExpressTM, Ver.1.0 (Applied Biosystems, Foster City, CA) and 
synthesized by Sigma Genosys Japan (Hokkaido, Japan). The sequences of primers 
and probes used in this study were indicated in Table 1 (page 71). All the probes 
contained a fluorescence reporter (6-carboxyfluorescein [FAM]) at the 5' end and a 
fluorescence quencher (6-carboxytetramethylrhodamine [TAMRA]) at the 3' end. 
Rodent GAPDH Control Reagents (Applied Biosystems) were used as an internal 
standard. Control RNA (Rodent, 50 ng/L) was serially diluted 5-fold with 1×TE 
(Wako) down to 80 pg/L. The amplification of standard and sample cDNA was 
carried out in a MicroAmp Optical 96-well reaction plate (Applied Biosystems). 
All standards and samples were assayed in duplicate. Each plate always contained 
the same standard. The threshold cycle (Ct) values were used to plot a standard 
curve in which Ct decreased in proportion to the log of the template copy number. 
The correlation coefficients of the standard curves were always more than 99%. 
 
Liver hydroxyproline content 
Liver tissue (approximately 400 mg of wet weight) was hydrolyzed in 4 mL of 
6 mol/L hydrochloric acid at 105°C overnight. The hydrolysate was centrifuged at 
800 g for 15 min and 20 L of the supernatant was evaporated under vacuum. 
Then, the sediment was dissolved in 0.6 mL of 50% isopropanol and incubated 
with 0.1 mL of chloramine-T solution, containing 42 mg of chloramine-T (Wako 
Pure Chemical Industries) dissolved in 6.9 mL of acetate-citrate buffer and 
0.21 mL of distilled water, for 10 min at room temperature. In turn, 0.5 mL of 
Ehrlich’s solution, including 5 g of p-dimethylaminobenzaldehyde (Wako Pure 
Chemical Industries) dissolved in 5.5 mL of 60% perchloric acid, and 26.8 mL 
isopropanol, were added and incubated at 50°C for 90 min. After cooling, the 
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absorbance was read at 558 nm. The hydroxyproline concentration was calculated 
from a standard curve prepared with high-purity hydroxyproline (Wako Pure 
Chemical Industries). Hydroxyproline levels were expressed in micrograms of 
hydroxyproline per gram liver. 
 
Histological analysis 
Histological analysis was performed in Histo. Science Laboratory Co., Ltd. 
(Tokyo, Japan) Formalin-fixed liver tissue was embedded in paraffin. Sections 
were stained with hematoxylin-eosin and Masson-trichrome. The severity was 
scored by a histopathologist. Hepatocellular degeneration and inflammation were 
scored as follows: 0, none; 1, slight; 2, mild; 3, moderate. Inflammation was 
indicated as the sum (0 to 6) of portal inflammation (score: 0 to 3) and lobular 
inflammation (score: 0 to 3). Fibrosis was indicated as follows: 1, pericellular and 
perivenular fibrosis; 2, focal bridging fibrosis; 3, bridging fibrosis with lobular 
distortion; 4, cirrhosis. 
 
Statistical analysis 
Results were expressed as the mean ± S.E. Student's t-test (when the F-test was 
significant, the Welch test was used) and Dunnett's test was used to compare two 
groups and three or more groups, respectively. The Wilcoxon test was used in 
histological analysis. p < 0.05 was considered statistically significant. The SAS 
System Release 8.2 (SAS Institute Inc.) was used for the statistical analyses. 
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Results 
 
 
Effects of SCD-1 inhibitor on liver SCD-1 activity and triglyceride 
accumulation in mice fed with lipogenic diets in vivo 
SCD-1 inhibitors were screened to obtain a research tool compound, and a lead 
compound reported by Xenon Pharmaceuticals, which had potent in vitro activity 
but low bioavailability, was structurally optimized as previously reported (Uto et 
al., 2010). As a result, a potent and orally-available SCD-1 inhibitor, compound A, 
was obtained, in which the 50% of inhibitory concentration was 51 nM. 
 In order to evaluate in vivo liver SCD-1 inhibition of compound A, I used 
mice fed with lipogenic diets based on high-carbohydrate and non-fat diets. After 
7 days feeding of lipogenic diets, compound A was administered to mice in a 
single oral dosing. Compound A inhibited liver SCD-1 activity in a dose dependent 
manner (Figure 4-A; page 79). The 50% inhibitory dose (ID50) was 17.2 mg/kg. 
Next, after 7 days feeding of lipogenic diets, compound A was orally administered 
once daily for 7 days during an additional 7 days feeding of the diets. Liver 
triglyceride content was increased 2-fold, and repeated dosing of compound A 
decreased high carbohydrate-induced triglyceride accumulation in the liver in a 
dose dependent manner (Figure 4-B; page 79). 
 
Evaluation of rats fed with MCD diets 
In order to evaluate the effects of SCD-1 on NASH pathology, Col1a1-Luc Tg rats 
were fed with lipogenic MCD diets and the time course of disease was confirmed 
to fix experimental conditions. Luciferase in the liver, reflecting collagen 
1a1-promoter activity, was measured to evaluate a pro-fibrogenic response in the 
liver of MCD rats. Luciferase in liver of MCD rats was significantly increased by 
3.3-fold at 8 weeks compared with control rats, although that at 2 weeks was not 
significantly increased (Figure 5-A; page 80). Liver triglyceride content in MCD 
rats were significantly increased at 2 and 8 weeks compared with control rats 
(Figure 5-B; page 80). Therefore, in the next study, MCD diets were fed for 8 
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weeks to rats in order to evaluate the effects of the SCD-1 inhibitor. 
 
Effects of SCD-1 on body weight change and liver weight in MCD 
rats 
In order to evaluate the effects of SCD-1 in the onset phase of NASH, Col1a1-Luc 
Tg rats were fed with lipogenic MCD diets for 8 weeks. SCD-1 inhibitor, 
compound A was administered once-daily to rats at doses of 30 and 100 mg/kg/day. 
The MCD diets caused body weight loss of 30% in the rats (Table 2; page 72). The 
treatment of the SCD-1 inhibitor did not affect the body weight change in rats fed 
with MCD diets. Neither MCD diets nor treatment of SCD-1 inhibitor significantly 
affected relative liver weight in MCD rats. 
 
Effects of SCD-1 on liver lipid accumulation in MCD rats 
In order to evaluate the effects of SCD-1 on liver triglyceride accumulation, the 
first process of NASH/NAFLD, liver triglyceride levels were evaluated. MCD 
diets increased triglyceride content in the livers of MCD rats by 12-fold, 
indicating remarkable lipid accumulation in the liver (Figure 6; page 81). A high 
dose of SCD-1 inhibitor significantly reduced triglyceride accumulation in the 
liver of MCD rats by 80%. These results indicate that SCD-1 is important in 
regulating liver triglyceride levels and its up-regulation may lead to the 
development of hepatic steatosis in MCD rats. 
 
Effects of SCD-1 on liver injury in MCD rats 
Next, I evaluated the effects of SCD-1 on phenotypes of NASH including liver 
injury, inflammation and fibrosis. In order to evaluate the effects of SCD-1 in liver 
injury, plasma markers, AST and ALT were measured. MCD diets increased the 
plasma AST and ALT levels by 3.3 and 5.5-fold, respectively (Figure 7; page 82) 
SCD-1 inhibitor at doses of 30 and 100 mg/kg/day prevented AST elevation by 
75% and 86%, respectively. Treatment of SCD-1 inhibitor at doses of 30 and 
100 mg/kg/day also prevented ALT elevation by 66% and 78%, respectively. These 
results indicate that the SCD-1 inhibitor prevents onset of liver injury after 
development of hepatic steatosis in MCD rats. 
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Effects of SCD-1 on histological changes including steatosis, 
hepatocellular degeneration and inflammation in liver of MCD rats 
I evaluated the effects of SCD-1 on histopathology in NASH by hematoxylin-eosin 
staining. MCD diets initiated severe steatosis in the liver of rats, which was 
detected as lipid droplets within hepatocytes, although it was not detected in the 
control group (Figure 8-A and 8-B; pages 83 and 84). Treatment of SCD-1 
inhibitor attenuated development of steatosis, shown as a reduction of lipid 
droplets in the liver, and it was remarkable in the high dose of the SCD-1 inhibitor 
group (Figure 8-C and 8-D; pages 83 and 84). Hepatocellular degeneration shown 
as ballooning or necrosis was also observed in the liver of rats fed with MCD diets, 
and administration of SCD-1 inhibitor attenuated the severity (Figure 9-A; 
page 85). Inflammatory cell infiltration was also observed in the liver of MCD rats, 
and it was rarely observed in a high dose of the SCD-1 inhibitor group 
(Figure 8-E and 8-F; pages 83 and 84, Figure 9-B; page 85). These results 
demonstrate that the SCD-1 inhibitor prevents the onset of crucial 
histopathological changes including hepatic steatosis, hepatocellular degeneration 
and inflammatory cell infiltration in MCD rats; therefore SCD-1 possibly 
contributes to NASH pathology including liver injury, inflammation as well as 
hepatic steatosis. 
 
Effects of SCD-1 on early fibrosis in the liver of MCD rats 
In order to evaluate the effects of SCD-1 on liver fibrosis, liver histology was 
evaluated by Masson-trichrome staining. Slight or mild fibrosis was observed in 
the liver of MCD rats (Figure 10-A; pages 86 and 87). Treatment of SCD-1 
inhibitor attenuated the development of these early fibrogenic changes 
(Figure 10-B and C; pages 86 and 87). Col1a1-Luc Tg rats were used to evaluate 
the effects on fibrosis easily and with the short-term period, and in the first study, 
luciferase in the liver was significantly increased after 8 weeks feeding of MCD 
diets as shown in Figure 5-A (page 80). Unfortunately, the luciferase in this study 
was not significantly changed in the liver of MCD rats although it showed 
tendency to increase (Figure 11-A; page 88). I suppose that fibrogenic change was 
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histologically very mild at 8 weeks feeding of MCD diets; therefore it failed to 
detect in luciferase. Hydroxyproline content, reflecting collagen protein levels, 
was also not increased in the liver of MCD rats (Figure 11-B; page 88). These 
results indicate that the SCD-1 inhibitor histologically prevents onset of early 
fibrosis in MCD rats, although it is necessary to study for longer time periods in 
order to fully evaluate the effects on more established liver fibrosis. 
 
Effects of SCD-1 on mRNA expression of MCP-1 in the liver of 
MCD rats 
Monocyte chemotactic protein-1 (MCP-1) is a key pro-inflammatory cytokine, 
which is concerned with various inflammatory responses including the liver 
disease. I evaluated the effects of SCD-1 on mRNA levels of MCP-1 in the liver of 
MCD rats by real time RT-PCR analysis. The mRNA levels of MCP-1 was 
drastically increased in the liver of MCD rats (Figure 12; page 89). A high dose of 
SCD-1 inhibitor significantly reduced the mRNA expression.  
 
SCD-1 mRNA expression in liver of MCD rats 
I evaluated the effects of MCD diets on mRNA levels of SCD-1 by real time 
RT-PCR analysis. SCD-1 mRNA levels were remarkably decreased in the livers of 
MCD rats compared with those of control rats (Figure 13; page 90). Its 
down-regulation is possibly due to protection against rapid triglyceride 
accumulation resulting from methionine and choline deficiency in the liver. 
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Discussion 
 
 
In this chapter, I demonstrated that SCD-1 has a key role in liver lipid 
accumulation and subsequent onset of liver injury, inflammation and fibrosis in 
NASH. I used a potent and orally-available SCD-1 inhibitor, compound A, 
obtained by lead optimization as previously reported (Uto et al., 2010). In order to 
measure the in vivo inhibitory activity of compound A to liver SCD-1, mice were 
fed with lipogenic diets based on high-carbohydrate and non-fat that up-regulate 
SCD-1 activity in the liver (Flowers et al., 2006, 2008). A single oral 
administration of compound A inhibited SCD-1 activity in the liver of mice fed 
with lipogenic diets. Liver triglyceride content was increased by 2-fold in the liver 
of mice fed with lipogenic diets for 14 days compared with standard chow diets. 
Repeated administration of the SCD-1 inhibitor for 7 days completely inhibited 
lipogenic diet-induced triglyceride accumulation in the liver.  
 My results are consistent with previous reports in SCD-1 deficient mice 
and pharmacological inhibition which were protective against triglyceride 
accumulation in the liver after feeding of lipogenic diets (Miyazaki et al., 2001a; 
Issandou et al., 2009). All of these previous reports used metabolic syndrome 
models with obesity and insulin resistance. I used NASH models to evaluate the 
effects of an SCD-1 inhibitor for the first time. In NASH rats fed with lipogenic 
MCD diets, SCD-1 inhibitor also inhibited triglyceride accumulation in the liver 
as well as metabolic syndrome models. Buque et al. reported that SCD-1 
expression levels were significantly correlated with the severity of fatty liver in 
obese rats (Buque et al., 2010). In human study, liver SCD-1 activities were also 
higher in obese patients with fatty liver than in those without fatty liver, and they 
were related to the percentage of liver fat (Kotronen et al., 2009). My results and 
these other reports suggest that SCD-1 plays a key role in regulating liver lipid 
levels in metabolic disorders including NASH/NAFLD. Liver specific disruption 
of SCD-1 as well as deficiency in the whole body was protective against lipid 
accumulation in the liver (Ntambi et al., 2002; Miyazaki et al., 2007). These 
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reflect that liver SCD-1 importantly regulates liver lipid levels. Interestingly, 
skin-specific disruption of SCD-1 but not adipose-specific one also protected 
against lipid accumulation in the liver by increasing fatty acid oxidation  
(Sampath et al., 2009; Flowers et al., 2012). In skin-specific deficiency of SCD-1, 
hepatic lipogenic response to high-carbohydrate diets were intact. In addition to 
liver, SCD-1 in skin and other organs possibly affects the development of hepatic 
steatosis in NASH/NAFLD in unknown ways other than increased hepatic 
lipogenesis. 
 Recent studies have focused on the involvement of SCD-1 in the 
development of hepatic steatosis; however there is little information about the 
contribution of SCD-1 to the development of NASH pathology. Therefore, I 
evaluated the effects of SCD-1 on the onset of NASH phenotypes including liver 
injury, inflammation and fibrosis. This is the first report that SCD-1 inhibition 
attenuated these pathology of NASH. MCD diets histologically developed 
hepatocellular degeneration and inflammatory cell infiltration in the liver of rats. 
Importantly, treatment of SCD-1 inhibitor attenuated these pathological 
observations in addition to plasma biomarkers of liver injury, AST and ALT in rats 
fed with MCD diets. MCP-1 is a pro-inflammatory cytokine and concerned with 
various inflammatory diseases including liver disease. In chronically injured liver 
including NASH, activated HSCs, key players in liver fibrosis, proliferate and 
continuously produce collagen. Additionally, activated HSCs also induce 
chemotaxis and activation of inflammatory cells such as monocytes/macrophages 
and T lymphocytes by production of inflammatory cytokines such as MCP-1 
(Marra et al., 1993; Czaja et al., 1994). HSCs can also migrate towards these 
cytokine chemoattractants (Marra et al., 1999). It was reported that the feeding of 
MCD diets to mice increased mRNA expression of MCP-1 in the liver (Zhang et 
al., 2009). In my present study, the mRNA expression of MCP-1 was also 
increased in the liver of rats fed with MCD diets. Treatment of SCD-1 inhibitor 
attenuated the MCD diets-induced MCP-1 up-regulation in the liver of rats. These 
results suggest that SCD-1 inhibition decrease sensitivity of the liver to 
pathogenesis of NASH including liver injury and inflammation after development 
of hepatic steatosis. 
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 It was previously reported that Col1a1-Luc Tg rats were useful as fibrosis 
models of the kidney and other organs, in which organ fibrosis was evaluated 
easily and in a short-term period (Terashima et al., 2010). In my present study, 
Col1a1-Luc Tg rats were used to evaluate pro-fibrogenic responses in livers of rats 
fed with MCD diets in a short-term period. In the first study to confirm 
experimental conditions, luciferase, reflecting collagen 1a1 promoter activity, in 
the liver was significantly increased after 8 weeks MCD diets. In the next study, 
the luciferase also showed a tendency to increase in rats fed with MCD diets for 8 
weeks, although it was not significant. The liver hydroxyproline levels, reflecting 
protein levels of collagen, also showed no changes in MCD rats. Therefore, to 
fully evaluate the effects on established fibrosis in these methods, a longer time 
period may be necessary. In contrast, histological analysis showed slight or mild 
fibrosis in the liver of MCD rats, and treatment of SCD-1 inhibitor prevented the 
onset of the early fibrosis. These results support that SCD-1 plays a key role in the 
onset of NASH pathology including liver injury, inflammation and early fibrosis.  
 Interestingly, SCD-1 inhibitor decreased triglyceride accumulation in the 
liver only in treatments with a high dose, but the liver injury, inflammation and 
early fibrosis were attenuated even in a low dose. I suppose that levels of 
triglyceride, which are a storage form of lipids, are not so important and those of 
free fatty acid cause liver injury and other pathology with NASH. Fatty acids are 
key mediators for hepatocyte lipotoxicity, and play a role in hepatocellular death, 
oxidative and endoplasmic reticulum stress, inflammation and fibrosis (Trauner et 
al., 2010). MUFAs are thought to be less toxic than saturated fatty acids, and it 
was reported that MUFAs protected cells against saturated fatty acids-induced 
apoptosis (Eitel et al., 2002). From this point of view, SCD-1 inhibition could 
increase the toxicity of fatty acids because SCD-1 activity could result in 
increased MUFAs and decreased saturated fatty acids. Unbalanced accumulation 
of saturated fatty acids resulting from decrease of SCD-1 were reported in the liver 
of mice fed with MCD diets, suggesting that depletion of MUFAs contribute to 
liver injury (Eitel et al., 2002). Furthermore, Li et al. reported that MCD diets in 
SCD-1 deficient mice increased hepatocellular apoptosis, liver injury and fibrosis 
although hepatic steatosis was ameliorated (Li et al., 2009). They suggested that 
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liver SCD-1 plays a key role in the prevention of liver injury by safely converting 
toxic fatty acids to MUFAs. In contrast, my results indicate that SCD-1 inhibition 
is protective against inflammation and liver injury in rats fed with MCD diets. 
Larter et al. reported that feeding of MUFA-rich diets did not prevent MCD 
diet-induced liver injuries in spite of an increased ratio of MUFAs in liver fatty 
acids (Larter et al., 2008). They suggested that accumulation of fatty acids per se 
may be important in liver injury, and it was not dependent on the nature of the 
fatty acid source. It was also reported that saturated fatty acids and MUFAs have 
similar effects on sensitization to TRAIL-induced apoptosis in cells (Malhi et al., 
2007). In human NASH, both saturated fatty acids and MUFAs are accumulated in 
the liver (Puri et al., 2007). These reports and our results show that MUFAs as 
well as saturated fatty acids also play a role in liver injury in NASH. One possible 
explanation for opposite results by Li et al. as described above is that toxicity by 
systemic inhibition of SCD-1 may contribute to SCD-1 deficiency-induced 
exacerbation of liver injury. It was recently reported that SCD-1 also seems to be 
concerned with inflammation in some organs (Liu et al., 2011). SCD-1 inhibitor 
did not cause inflammation; however other compounds with more potent systemic 
inhibition of SCD-1 increased white blood cells (Uto et al., 2011). Importantly, 
these potent compounds reduced the beneficial effects on plasma triglyceride 
levels. These findings show that toxic effects of systemic inhibition of SCD-1 
possibly cancel the beneficial effects. Another explanation is the differences 
between genetic disruption and pharmacological inhibition. Inborn and complete 
deficiency of SCD-1 with genetic disruption might be not applicable to evaluate 
the pathology of NASH because environmental and life style related factors are 
involved in most of the elderly patients. 
 Liver lipid levels are mainly regulated by four processes such as fatty acid 
uptake into the liver, de novo lipogenesis, VLDL secretion from the liver and fatty 
acid oxidation. In human obesity with NAFLD, the main mechanism of liver lipid 
accumulation is possibly due to increased fatty acid uptake and de novo 
lipogenesis caused by insulin resistance. In contrast, MCD diets induce liver 
triglyceride accumulation by mainly decreased triglyceride secretion from the 
liver as VLDL and increased fatty acid uptake (Rinella et al., 2008). In my present 
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study, mRNA expression of SCD-1 in the liver of rats fed with MCD diets was also 
remarkably decreased as previously reported in mice fed with MCD diets (Rizki et 
al., 2006). Triglyceride accumulation in the liver is much more rapid in those fed 
with MCD diets than general lipogenic diets containing normal levels of 
methionine and choline. Therefore, one possible explanation is that 
down-regulation of SCD-1 after feeding of MCD diets may be a protective 
mechanism against rapid triglyceride accumulation. Importantly, the SCD-1 
inhibitor effectively inhibited liver triglyceride accumulation in rats fed with MCD 
diets in spite of a remarkably decreased mRNA expression of SCD-1 and also 
presumably decreased the enzymatic activity. I suppose that SCD-1 inhibition 
decreased liver triglyceride accumulation in MCD rats resulting from a change of 
balance in these processes of fatty acid metabolism in the liver, although the 
contribution of SCD-1 might be reduced in these models compared with human 
patients. It is known that generally used lipogenic diets such as high-fat or 
high-carbohydrate or insulin resistant/diabetic animals such as ob/ob, db/db or 
ZDF cause hepatic steatosis but no steatohepatitis with fibrosis; therefore I used 
MCD diet models in my present study although SCD-1 expression showed an 
opposite change. It was recently reported that long-term feeding of 
cholesterol-containing atherogenic diets to mice induced liver injury, 
inflammation and fibrosis, in which induced SCD-1 expression through dietary 
cholesterol-induced LXR activation and subsequent increased hepatic lipogenesis 
were involved (Matsuzawa et al., 2007). I suppose potent beneficial effects of 
SCD-1 inhibitors in such SCD-1 up-regulated NASH models. 
 In summary, an SCD-1 inhibitor prevented hepatic steatosis and 
subsequent pathology including liver injury, inflammation and fibrosis in NASH 
(summarized in Figure 14; page 91). These results demonstrate that SCD-1 plays 
an important role in the onset process of NASH. 
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Chapter II 
“Effects of angiotensin II on the 
progression of liver fibrosis” 
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Introduction 
 
 
Ang II is a major component of renin-angiotensin systems (RAS), which contain 
angiotensinogen, renin, angiotensin I, angiotensin-converting enzyme (ACE) and 
Ang II receptors. Ang II and RAS play central roles in the regulation of systemic 
blood pressure and fluid homeostasis by vasoconstriction of smooth muscle cells 
and sodium retension (Brewster et al., 2003). In addition to these “systemic RAS”, 
“local RAS” are regulated within individual organs including the liver and is 
thought to play an important role in the local response to disease (Paul et al., 
2006). The action of Ang II is mainly mediated by two subtypes of receptors, 
angiotensin II type 1 (AT1) and type 2 (AT2) receptors, which are distributed in 
many kinds of organs and tissues. The action of Ang II primarily is mediated by 
AT1 receptor (Mehta and Griendling, 2007). AT2 receptor generally have 
divergent pathways compared with AT1 receptor.  
 Several lines of evidence have suggested that RAS also plays an important 
role in the pathogenesis of organ fibrosis (Brilla, 2000; Sun et al., 2000). In 
mesangial cells and other cell types, Ang II has been shown to promote the 
proliferation and collagen synthesis (Ray et al., 1991; Wolf et al., 1992; Kagami et 
al., 1994; Weber et al., 1994; Tharaux et al., 2000). Additionally, the expression of 
TGF-1, the key cytokine in the development of cardiac and renal fibrosis, is 
increased by Ang II (Weber, 1997). Blockade of RAS with ACE inhibitors or 
angiotensin receptor blockers (ARBs) has been shown to ameliorate the 
progression of organ fibrosis (Ishidoya et al., 1995; Kim et al., 1995; Molteni et al., 
2000).  
 In the liver, Ang II is considered to regulate intrahepatic circulation 
(Schneider et al., 1999). It has been also reported that Ang II induces proliferation 
and contraction of human HSCs, key players in liver fibrosis (Bataller et al., 2000). 
Additionally, ACE inhibitors or ARBs were shown to attenuate the progression of 
liver fibrosis in vivo (Ramos et al., 1994; Jonsson et al., 2001; Ohishi et al., 2001; 
Paizis et al., 2001; Yoshiji et al., 2002). These reports suggested that Ang II and 
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RAS might play an important role in the pathogenesis of liver fibrosis including 
NASH. However, the precise molecular mechanism of Ang II-mediated liver 
fibrosis and activation of HSCs were poorly understood.  
 Bile duct ligation (BDL) is generally used as liver fibrosis models. BDL 
stimulates proliferation of bile duct epithelial cells and finally causes portal 
inflammation and fibrosis (Peter, 2011). BDL model does not show hepatic 
steatosis and related metabolic disorders, and are pure fibrosis models. It was 
reported that key elements of RAS including ACE and AT1 receptors were 
up-regulated in the liver of BDL rats, indicating possible contribution of RAS to 
fibrosis in the model (Paizis et al., 2002). The comparison of BDL model with 
MCD model used in “Chapter I” is 1 in Table 3 (page 73). In my present study, I 
used BDL models to purely evaluate progression of liver fibrosis, although it is 
necessary to evaluate in MCD models.  
 Olmesartan medoxomil (olmesartan), (5-methyl-2-oxo-1,3-dioxolen -4-yl) 
methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)-phenyl] 
phenyl}methylimidazol-5-carboxylate, is a potent ARB and is commercially used 
as an antihypertensive agent globally. Olmesartan is a prodrug containing an ester 
moiety which is rapidly cleaved to release the active form of olmesartan, 
RNH-6270, after oral administration (Mizuno et al., 1995). Chemical structures of 
olmesartan and RNH-6270 were shown in Figure 15 (page 92). 
 In this chapter, in order to elucidate the molecular mechanism of 
Ang II-mediated liver fibrosis progression, I evaluated the effects of Ang II on in 
vivo liver fibrosis models and in vitro activated HSCs using ARB, olmesartan. 
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Materials and Methods 
 
 
Synthesis of olmesartan and RNH-6270 
Olmesartan and its active metabolite, RNH-6270 were discovered and synthesized 
in Sankyo Co., Ltd. 
 
Animals 
All animal experiments were performed in accordance with the Animal 
Experimentation Guidelines of Sankyo Co., Ltd. Sprague-Dawley (SD) male rats 
were purchased from Japan SLC Inc. (Shizuoka, Japan), and maintained in a room 
under a temperature controlled at 23°C ± 2 and a 12-hour light-dark lighting cycle. 
The animals were allowed a standard pellet chow and water ad libitum. Anesthesia 
was performed by intraperitoneally injecting pentobarbital (Dainippon 
Pharmaceutical) at a dose of 50 mg/kg. 
 
Rats with common bile duct ligation 
Liver fibrosis was induced by common bile duct ligation, as previously described 
(Kountouras et al., 1984). SD male rats (200 to 250 g body weight) were used. The 
common bile duct was double-ligated and cut between the ligatures. In the first 
experiment, some rats received BDL and others received a sham-operation, in 
which they were subjected to a midline incision and manipulation of the common 
bile duct without ligation. Rats were divided into six groups and sacrificed at 
indicated times (1 to 3 weeks) after surgery under anesthesia as follows: 
 Group 1: Sham sacrificed at 1 week (n =3) 
 Group 2: BDL sacrificed at 1 week (n = 3) 
 Group 3: Sham sacrificed at 2 weeks (n = 5) 
 Group 4: BDL sacrificed at 2 weeks (n = 6) 
 Group 5: Sham sacrificed at 3 weeks (n = 5) 
 Group 6: BDL sacrificed at 3 weeks (n = 5) 
In the second experiment, rats were divided into three groups at 7 days after 
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surgery as follows:  
 Group 1: Sham group (n = 5) 
 Group 2: BDL group (n = 10) 
 Group 3: BDL + ARB group (n =10) 
In Group 3, olmesartan, dissolved in a solution of 0.5% carboxymethyl cellulose 
(CMC, Nacalai Tesque, Kyoto, Japan), was orally administered at a dose of 
1 mg/kg six times a week from 7 days to 20 days after the surgery. In Group 1 and 
2, rats received the vehicle for the same time period. Rats were sacrificed at 21 
days after surgery under anesthesia. Blood was collected from the aorta, and 
plasma was prepared by centrifugation. Plasma samples were frozen and stored at 
–80°C. The livers were washed with saline and weighed. The specimens of liver 
were immediately snap-frozen and stored at –80°C for real time RT-PCR analysis 
and measurement of hydroxyproline content. Portions of liver lobes were also 
fixed in 10% buffered formalin (Wako Pure Chemical Industries) and embedded in 
paraffin for histological analysis. 
 
Liver hydroxyproline content 
Liver tissue (approximately 400 mg of wet weight) was hydrolyzed in 4 mL of 
6 mol/L hydrochloric acid at 105°C overnight. The hydrolysate was centrifuged at 
800 g for 15 min and 20 L of the supernatant was evaporated under vacuum. 
Then, the sediment was dissolved in 0.6 mL of 50% isopropanol and incubated 
with 0.1 mL of chloramine-T solution, containing 42 mg of chloramine-T (Wako 
Pure Chemical Industries) dissolved in 6.9 mL of acetate-citrate buffer and 
0.21 mL of distilled water, for 10 min at room temperature. In turn, 0.5 mL of 
Ehrlich’s solution, including 5 g of p-dimethylaminobenzaldehyde (Wako Pure 
Chemical Industries) dissolved in 5.5 mL of 60% perchloric acid, and 26.8 mL 
isopropanol, were added and incubated at 50°C for 90 min. After cooling, the 
absorbance was read at 558 nm. The hydroxyproline concentration was calculated 
from a standard curve prepared with high-purity hydroxyproline (Wako Pure 
Chemical Industries). Hydroxyproline levels were expressed in micrograms of 
hydroxyproline per gram liver. 
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Plasma AST and ALT 
AST and ALT levels in the plasma were measured using an Autoanalyzer (Hitachi 
7250, Hitachi High-Technologies Corporation). 
 
Histological analysis 
Liver sections were incubated with xylene and hydrated through several washes in 
ethanol and distilled water to remove the paraffin. The sections were either stained 
with Masson-trichrome or subjected to immunohistostaining using antibodies 
against -SMA or AT1 receptor. For AT1 immunohistostaining, sections were 
heated with 10 mmol/L sodium citrate buffer (pH 6.0) at 120°C for 10 min. 
Endogenous peroxidase activity was quenched by the addition of 3%(v/v) 
hydrogen peroxide for 5 min. Unspecific binding sites were blocked by Block Ace 
(Dainippon Pharmaceutical) for 30 min. Polyclonal anti-rabbit AT1 (Santa Cruz 
Biotechnology, Santa Cruz, CA) diluted 1:200 in Block Ace was used. The 
sections were incubated for 30 min with the primary antibody at room temperature, 
the secondary antibody (goat anti-rabbit IgG, biotinylated, Santa Cruz; diluted 
1:100 in Block Ace) for 30 min, and finally, with peroxidase-conjugated 
streptavidin (Nichirei, Tokyo, Japan). For -SMA immunohistostaining, after 
endogenous peroxidase inactivation, sections were incubated for 60 min with 
mouse monoclonal anti-human smooth muscle actin/HRP (DAKO Japan, Kyoto, 
Japan) at room temperature. The immunoreactivity was detected by the addition of 
3,3'-diaminobenzidine tetrahydrochloride (DAB, DAKO Japan) at room 
temperature. Between each step, the sections were washed three times with 
tris-buffered saline (TBS, DAKO Japan) for 5 min. The sections were 
counterstained with Carazzi's hematoxylin (Muto Pure Chemicals, Tokyo, Japan), 
dehydrated and mounted. 
 
Isolation of rat hepatic stellate cells 
Rat HSCs were prepared from SD male rats (>500 g body weight) using the 
method of Kawada et al. with some modifications (Kawada et al., 1998). The liver 
was perfused through the portal vein with Ca2+- and Mg2+-free Hanks' balanced 
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salts solution (HBSS; Sigma Chemical Co., St. Louis, MO) containing 0.06% 
EGTA at a flow rate of 10 mL/min at 37°C for 10 min. The liver was then perfused 
with HBSS containing 0.1% pronase E (Merck, Damstadt, Germany), followed by 
0.02% pronase E and 0.125% collagenase (type IV; Sigma). After perfusion, the 
digested liver was excised, minced, and incubated with gentle stirring in HBSS 
containing 0.05% pronase E, 0.05% collagenase, 20 g/mL Dnase I (Roche 
Diagnostics, Mannheim, Germany) for 30 min at pH 7.3. After passage through a 
mesh with a pore size of 150 m in diameter, the cells were centrifuged twice at 
400 g in Gey's balanced salts solution (GBSS) at 4°C for 7 min. The HSC-enriched 
fraction was obtained by centrifugation in GBSS containing 8.2% Nycodenz 
(Daiichi Pure Chemicals) at 1,400 g for 20 min. The HSCs in the upper white layer 
were washed twice by centrifugation. The cells were cultured in Dulbecco's 
modified Eagle medium (DMEM; Gibco BRL, Grand Island, NY) containing 10% 
fetal calf serum (FCS), 100 g/mL gentamicin sulfate (Gibco BRL), 100 g/mL 
streptomycin sulfate and 100 units/mL penicillin G sodium (Gibco BRL) on 
96-well or 6-well tissue culture plates (FALCON, Beckton Dickinson, Franklin 
Lakes, NJ) at 37°C under a 5% CO2 atmosphere. The culture medium was replaced 
at 2 days after plating and then every 2 to 3 days. Before reaching confluence, the 
cells were used in each experiment. 
 
Cell proliferation 
The proliferation rate of HSCs was determined by measuring the amount of 
[3H]-thymidine incorporated into the cellular DNA. The media were replaced with 
serum-free DMEM containing angiotensin II (human, Sigma) with or without 
RNH-6270 and then pulsed for 48 hrs with 0.5 Ci/mL [methyl-3H]-thymidine 
(Daiichi Pure Chemicals). At the end of the pulsing period, the plates were frozen 
and stored at –80°C. After thawing, the cells were incubated with 0.05% 
trypsin/0.53 mmol/L EDTA solution (Gibco BRL) at 37°C. Cellular DNA was then 
fixed on a glass filter (Filtermat A, PerkinElmer Inc., Waltham, MA) using a cell 
harvester (Harvester 96, Hamden, CT). The radioactivity was measured by a liquid 
scintillation counter (Betaplate 1205, PerkinElmer Inc.). 
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Collagen synthesis 
The rate of collagen synthesis in HSCs was determined by measuring the amount 
of [3H]-proline incorporated into collagenase-digestible macromolecules. The 
media were replaced with Ang II in serum-free DMEM containing 0.5 mmol/L 
3-aminopropionitrile (Tokyo Kasei Kogyo, Tokyo, Japan) and 0.1 mmol/L 
L-ascorbic acid (Sigma) in the presence or absence of RNH-6270, and then pulsed 
for 48 hrs with 0.5 Ci/mL L-[2,3,4,5-3H]-proline (Daiichi Pure Chemicals). At 
the end of the pulsing period, the plates were frozen and stored at –80°C. After 
thawing, the cells were precipitated twice with 10% trichloroacetic acid (TCA; 
Nacalai Tesque, Kyoto, Japan) by centrifugation and washed twice with 
ethanol-ether (3:1) mixture. After drying overnight, the pellet was digested with 
5 mg/mL collagenase type VII (Sigma), dissolved in 50 mmol/L Tris-HCl, and 
5 mmol/L CaCl2, at pH 7.4, and at 37°C for 90 min, and precipitated twice with 
10% TCA and 5% tannic acid (Sigma) by centrifugation. The supernatants from 
the two centrifugations were pooled, and 50 L of the mixture was placed on a 
Deepwell LumaPlate (PerkinElmer Inc.). After drying overnight, the radioactivity 
was counted by a microplate scintillation counter (TopCount HTS, PerkinElmer 
Inc.). 
 
Measurement of TGF-1 
In the in vitro experiments, HSCs were incubated with Ang II in the presence or 
absence of RNH-6270 or platelet-derived growth factor-BB (PDGF-BB, rat; R&D 
Systems, Minneapolis, MN), which is a homodimer of PDGF-B chain subunit and 
the most potent mitogen for HSCs, for 48 hrs. Culture supernatants were collected, 
frozen and stored at –80°C. In order to quantify total TGF-1, the supernatants 
were treated with 1 mol/L HCl for 10 min to convert the latent form of TGF-1 to 
the active form and neutralized with 1.2 mol/L NaOH and 0.5 mol/L HEPES. In 
the in vivo experiments, plasma samples were treated with 2.5 mol/L acetic acid 
for 10 min and neutralized with 2.7 mol/L NaOH and 1 mol/L HEPES. The 
activated samples were measured using TGF-1 Human, Biotrak ELISA System 
(Amersham Biosciences, Piscataway, NJ) according to the manufacturer's 
instructions. 
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Real time PCR analysis 
In the in vitro experiments, HSCs were incubated with Ang II in the presence or 
absence of RNH-6270 for 24 hrs. and total cellular RNA was isolated after lysis of 
the cells. In the in vivo experiments, total RNA was isolated from homogenates of 
whole livers at Day 21 after surgery. RNA extraction was performed using 
TRIZOL reagent (Gibco BRL) according to the manufacturer's instructions. RNA 
purity and concentration were determined using a spectrophotometer (DU 7500, 
Beckman Coulter, Inc., Brea, CA). Total RNA was converted to complementary 
DNA (cDNA) with TaqMan Reverse Transcription Reagents (Applied Biosystems) 
using GeneAmp PCR System 9600 (PerkinElmer Inc.). For cDNA synthesis, 5 g 
total RNA, 10 L 10×RT buffer, 22 L MgCl2 (25 mM), 20 L dNTPs mixture 
(10 M each), 5 L random hexamers (50 M), 2 L RNase inhibitor (20 U/L), 
and 2.5 L (50 U/L) Moloney Murine Leukemia Virus Reverse Transcriptase 
were added to make a total volume of 100 L. Samples were incubated at 25°C for 
10 min and 48°C for 30 min. Reactions were stopped by heating to 95°C for 5 min. 
The fluorescent TaqMan probes, and forward and reverse primers were designed 
with the software, Primer ExpressTM, Ver.1.0 (Applied Biosystems, Foster City, 
CA), and synthesized by Sigma Genosys Japan (Hokkaido, Japan). Sequences of 
primers and probes used in this study are shown in Table 1 (page 71). I used a 
probe and primers from the Rodent GAPDH Control Reagents (Applied 
Biosystems) for internal calibration. Two-step PCR was carried out using an ABI 
PRISM 7700 Sequence Detector System (PerkinElmer Inc.). PCR conditions were 
as follows: 5 L cDNA solution, 25 L TaqMan 2×PCR Master Mix (Applied 
Biosystems), 0.5 L forward primer (10 M), 0.5 L reverse primer (10 M), and 
0.5 L probe (20 M) were added to make a total volume of 50 L. The thermal 
cycler conditions were 2 min at 50°C, 10 min at 95°C, and 40 cycles of 15 sec at 
95°C followed by 1 min at 60°C. Standard curves to determine the mRNA content 
were generated using the GAPDH control. Control RNA (Rodent, 50 ng/L) was 
serially diluted 5-fold with 1×TE (Wako) down to 80 pg/L. The amplification of 
standard and sample cDNA was carried out in a MicroAmp Optical 96-well 
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reaction plate (Applied Biosystems). All standards and samples were assayed in 
duplicate. Each plate always contained the same standard. The threshold cycle (Ct) 
values were used to plot a standard curve in which Ct decreased in proportion to 
the log of the template copy number. The correlation coefficients of the standard 
curves were always more than 99%. 
 
Statistical analysis 
Results were expressed as the mean ± S.E. Student's t-test (when the F-test was 
significant, the Welch test was used) and Dunnett's test was used to compare two 
groups and three or more groups, respectively. p < 0.05 was considered 
statistically significant. The SAS System Release 8.2 (SAS Institute Inc.) was used 
for the statistical analyses. 
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Results 
 
 
Time course evaluation of in vivo liver fibrosis models with BDL 
I used BDL model as in vivo liver fibrosis models. In order to confirm 
experimental conditions in BDL rats, the time course of disease progression was 
evaluated up to 3 weeks after BDL. Liver hydroxyproline content, reflecting 
collagen protein levels, was increased by 1.9-fold at 1 week after BDL compared 
with sham-operated rats (Figure 16; page 93). Liver hydroxyproline content at 
both 2 and 3 weeks increased by 2.5-fold. Plasma AST levels at 1, 2 and 3 weeks 
increased by 3.0, 3.1 and 4.0-fold in BDL rats compared with Sham rats, 
respectively (Figure 17; page 94). In contrast, plasma ALT levels were not 
significantly changed. Body weight in BDL rats was remarkably decreased for the 
first 4 days after BDL presumably due to surgical complications although no 
animals died (Figure 18; page 95). In the next study, fibrosis was evaluated at 3 
weeks after surgery, and the treatment of compounds started at 7 days after surgery 
considering surgical damage. 
 
Effects of Ang II on survival rate, body weight change and liver 
weight in BDL rats in vivo 
In order to evaluate the effects of Ang II on liver fibrosis in vivo, ARB, olmesartan 
was orally administered at a dose of 1 mg/kg starting at 7 days after BDL. 
However, two animals in the BDL group and three animals in the ARB-treated 
group died up to Day 11 after BDL presumably due to surgical complications. The 
survival rate was not statistically different between these two groups (Fisher’s 
exact test). Final body weight was significantly lower than those in the BDL group 
compared with the Sham group, but ARB treatment did not significantly affect 
them (Table 4; page 74). The ratio of liver weights to body weights increased in 
the BDL group by 1.8-fold, which is presumably due to inflammation and fibrosis. 
It was significantly lower in the ARB-treated group compared with the BDL 
group. 
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Effects of Ang II on liver fibrosis in BDL rats in vivo 
I evaluated the effects of Ang II on liver fibrosis in BDL rats in vivo. First, 
collagen levels were measured as hydroxyproline content in the livers of BDL rats. 
Liver hydroxyproline content in the BDL group increased by 1.8-fold compared 
with the Sham group, indicating development of fibrosis (Figure 19; page 96). 
ARB treatment decreased collagen accumulation by 45%. These results suggest 
that Ang II mediates progression of liver fibrosis in BDL rats through activation of 
AT1 receptors. 
 Histological analysis was performed in the liver of BDL rats. Bile duct 
proliferation was remarkable in the livers of the BDL group resulting from 
cholestasis after BDL, and it was minimal in the ARB group (Figure 20-A; 
page 97). Masson-trichrome staining showed that collagen deposition spread from 
the area of bile duct proliferation in the BDL liver, and ARB treatment decreased 
the area of fibrosis (Figure 20-A; page 97). These observations were consistent 
with the results in liver hydroxyproline content, indicating ARB ameliorated liver 
fibrosis in BDL rats. Activated HSCs are key players in liver fibrosis and 
continuously produce collagen and ECMs. Therefore, in order to identify activated 
HSCs in the BDL liver, immunostaining for -SMA, a marker protein of activated 
HSCs, was performed. The number of -SMA-positive cells, indicating activated 
HSCs, were remarkably increased  in the liver of BDL rats compared with the 
Sham group (Figure 20-B; page 97). These cells were localized in the area of 
collagen deposition. ARB treatment reduced the number of -SMA-positive cells 
in the liver of ARB group. Next, in order to identify expression and distribution of 
AT1 receptors, immunostaining for AT1 receptor was performed. AT1 receptors 
were highly expressed in the livers of BDL rats and almost not in the Sham group 
(Figure 20-C; page 97). Importantly, AT1 receptors were localized in the area of 
collagen deposition and accumulation of -SMA-positive cells. ARB treatment 
reduced AT1 receptor positive-cells. These results suggest that activated HSCs 
expressing AT1 receptors may have a key role in the development of liver fibrosis 
with stimulation of Ang II in the liver. 
 Next, I evaluated mRNA levels of key fibrosis-related genes, collagen 1a1 
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and α-SMA, in the liver of ARB-treated BDL rats by real time RT-PCR. Collagen 
1a1 and α-SMA mRNA levels were increased in the BDL group by 3.7 and 
3.8-fold compared with the Sham group, respectively, and ARB treatment reduced 
the expression of them by 44% and 52%, respectively (Figure 21; page 98). These 
results are consistent with the histological results in that collagen deposition, 
α-SMA-positive cells and hydroxyproline content were reduced. 
 TGF-1 is a key pro-fibrogenic cytokine and is thought to stimulate 
activation of HSCs, in particular collagen production in HSCs. Therefore, I 
evaluated plasma TGF-1 levels in ARB-treated BDL rats. Plasma TGF-1 levels 
were increased in the BDL group by 1.7-fold compared with the Sham group, and 
ARB treatment reduced them by 79% (Figure 22; page 99). These results indicate 
that Ang II is involved in plasma TGF-1 elevation in vivo. 
 
Effects of Ang II on liver injury in BDL rats in vivo 
In order to evaluate the effects of Ang II on liver injury, plasma markers of liver 
injury were measured. Plasma AST and ALT levels were increased in the BDL 
group by 5.3 and 2.6-fold compared with the Sham group, respectively (Figure 23; 
page 100). However, ARB treatment did not significantly change plasma AST and 
ALT levels. These results indicate that ARB did not directly ameliorate liver injury 
in BDL rats. Therefore, the anti-fibrotic effects of ARB were not secondary ones 
due to hepatoprotection. 
 
Effects of Ang II on proliferation and collagen synthesis in 
activated HSCs in vitro 
In the in vivo experiments, possible fibrogenic effects of Ang II were shown. Next, 
in order to investigate the mechanism of fibrogenic action of Ang II, I evaluated 
the effects of Ang II on activated HSCs in vitro. HSCs were prepared from rats by 
collagenase-pronase perfusion and cultured. Isolated HSCs show a quiescent 
phenotype with a round shape and stored vitamin A within the cells. Cultured 
HSCs on plastic dishes were spontaneously activated during several days and 
thereafter used for experiments. Olmesartan is a prodrug that converts to an active 
metabolite in blood. Therefore, a pharmacologically active form of olmesartan, 
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RNH-6270 was used in the in vitro experiments.  
 First, I evaluated the effects of Ang II on proliferation and collagen 
synthesis as typical and crucial phenotypes of activated HSCs. Ang II treatment 
stimulated proliferation of activated HSCs, measured as [3H]thymidine 
incorporation into cells (Figure 24; page 101). ARB treatment completely blocked 
the Ang II-stimulated proliferation in activated HSCs. Ang II treatment also 
stimulated collagen synthesis in activated HSCs, measured as [3H]proline 
incorporation (Figure 25; page 102). ARB treatment almost completely blocked 
the Ang II-induced collagen synthesis in activated HSCs. These results 
demonstrate that Ang II stimulates typical fibrogenic phenotypes including 
proliferation and collagen synthesis in activated HSCs through activation of AT1 
receptors. 
 
Effects of Ang II on autocrine production of pro-fibrogenic 
cytokines in activated HSCs in vitro 
TGF-1 plays a central role in transformation of HSCs to myofibroblast-like 
phenotypes in a paracrine manner. Furthermore, activated HSCs secrete TGF-1 
and stimulate self-activation in an autocrine manner. Therefore, I evaluated the 
effects of Ang II on production of TGF-1 in activated HSCs. Ang II increased 
TGF-1 levels in culture supernatants in a dose-dependent manner (Figure 26-A; 
pages 103 and 104). PDGF is the most potent mitogen for HSCs; therefore I 
evaluated TGF-1 production after PDGF treatment. PDGF increased TGF-1 
production in activated HSCs in my present study. Interestingly, Ang II and PDGF 
additively stimulated TGF-1 production in activated HSCs. ARB treatment 
almost completely blocked the Ang II-induced TGF-1 production in activated 
HSCs (Figure 26-B; pages 103 and 104). 
 In addition to TGF-1, CTGF is also a key pro-fibrogenic cytokine in 
activated HSCs. Therefore, I evaluated the effects of Ang II on mRNA expression 
of CTGF in activated HSCs. Ang II treatment significantly increased mRNA 
expression of CTGF in activated HSCs (Figure 27; page 105). ARB treatment 
completely blocked Ang II-induced CTGF mRNA expression. These results 
suggest that up-regulation of TGF-1 and CTGF possibly mediates fibrogenic 
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action of Ang II in activated HSCs. 
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Discussion 
 
 
In this chapter, I demonstrated that Ang II plays a key role in the progression of 
liver fibrosis mediated through stimulation of proliferation and collagen synthesis 
of activated HSCs. I showed that ARB, olmesartan ameliorated liver fibrosis in 
BDL rats. During the same period as my research, two other groups had also 
reported anti-fibrotic effects of ARB in liver in vivo (Paizis et al., 2001; Yoshiji et 
al., 2001). Paizis et al. used BDL models to evaluate ARB, irbesartan just like my 
study. They showed that ARB reduced mRNA levels of collagen 1a1 in the liver; 
however they failed to show decrease of collagen protein levels or amelioration of 
liver histology. In contrast, I showed that olmesartan surely attenuated liver 
fibrosis histologically and decreased collagen protein levels as well as mRNA 
levels of collagen 1a1 of BDL rats. Yoshiji et al. also reported that ARB, 
candesartan, inhibited progression of liver fibrosis in pig-serum models. My 
results and their findings indicate key roles of Ang II in liver fibrosis through 
activation of AT1 receptors. In my present study, ARB did not significantly affect 
plasma markers of liver injury, AST and ALT, although ARB ameliorated liver 
fibrosis. These results exclude the possibility of indirect effects of ARB on liver 
fibrosis mediated through hepatocellular protection. 
 In order to elucidate the mechanism of fibrogenic action of Ang II, I 
evaluated the effects of Ang II and ARB on typical phenotypes of activated HSCs 
in vitro. Quiescent HSCs in normal livers are not or scarcely proliferating; 
however activated HSCs in injured livers are highly proliferating. Batallar et al. 
reported that Ang II stimulated proliferation of human HSCs (Bataller et al., 2000). 
I also demonstrated that Ang II treatment stimulated proliferation of activated 
HSCs in vitro, measured as [3H]thymidine incorporation into cells, and ARB 
treatment completely blocked them. In an injured liver, activated HSCs 
continuously produce collagen and other ECM that lead to development of liver 
fibrosis. Ang II treatment also stimulated collagen synthesis measured as 
[3H]proline incorporation, and ARB treatment blocked them. I showed for the first 
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time that Ang II stimulated collagen production, which is the most crucial 
phenotype of activated HSCs.  
 TGF-1 is highly involved in the pathogenesis of liver fibrosis. TGF-1 
mainly stimulates the activation and collagen synthesis of HSCs in an autocrine or 
a paracrine manner (Matsuoka and Tsukamoto, 1990; Gressner, 1995). In BDL 
model, TGF-1 expression was up-regulated in the liver and HSCs were shown to 
be their main source of production (Bissell et al., 1995). In other organs such as 
the kidney and heart, the expression of TGF-1 was increased with stimulation of 
Ang II (Weber, 1997). Furthermore, Yoshiji et al. showed that ARB treatment 
decreased protein levels of TGF-1 in the liver of fibrotic rats (Yoshiji et al., 
2001). I also showed that plasma levels of TGF-1 were increased in BDL rats in 
vivo and ARB treatment attenuated them. Additionally, I showed that Ang II 
treatment increased TGF-1 production of activated HSCs in vitro. PDGF is the 
most potent mitogen for HSCs (Pinzani, 2002; Borkham-Kamphorst et al., 2007). 
PDGF also induced TGF-1 production in activated HSCs in my present study. 
Interestingly, PDGF treatment potentiated the Ang II-induced TGF-1 production. 
These results suggest that Ang II and PDGF may jointly stimulate activated 
phenotypes including TGF-1 production in HSCs and lead to development of 
liver fibrosis. ARB treatment almost completely blocked the Ang II-induced 
TGF-1 production in activated HSCs in vitro and additionally inhibited increased 
plasma TGF-1 levels in BDL rats in vivo. CTGF is also thought to stimulate 
activation of HSCs (Paradis et al., 1999; Williams et al., 2000; Paradis et al., 
2002). My results indicated for the first time that Ang II treatment up-regulates 
mRNA expression of CTGF in activated HSCs. These results suggest that the 
Ang II-stimulated collagen synthesis is mediated through up-regulation of two 
pro-fibrogenic cytokines, TGF-1 and CTGF, to some extent in an autocrine 
manner. All of these actions were mediated through activation of AT1 receptors 
because all of them were blocked with ARB treatment. 
 Histological analyses showed remarkable collagen deposition in the liver 
of BDL rats. The -SMA-positive cells, indicative of activated HSCs, were 
accumulated in the area of collagen deposition. The mRNA levels of -SMA were 
also up-regulated in the liver of BDL rats. These results support that proliferating 
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and activated HSCs are involved in development of fibrosis in the liver of BDL 
rats. ARB treatment decreased accumulation of -SMA-positive cells and mRNA 
expression of -SMA as well as collagen deposition, suggesting that Ang II and 
AT1 receptors contribute to the activation and proliferation of HSCs in the liver of 
BDL rats. As expected, -SMA-positive cells seemed to express AT1 receptors 
based on the AT1 immunostaining. Paizis et al. also reported remarkable 
expression of AT1 receptors and other RAS components in the fibrotic area in the 
liver of BDL rats (Paizis et al., 2002). Furthermore, activated, but not quiescent, 
HSCs highly expressed RAS components and synthesized Ang II (Bataller et al., 
2003b). Therefore, activation of local RAS in the liver after liver injury may play 
a key role in liver fibrosis in chronic liver diseases including NASH. My data and 
these other reports demonstrated that activated HSCs expressing AT1 receptors, in 
response to Ang II, play a key role in the progression of liver fibrosis. Particularly, 
I showed that Ang II stimulated collagen synthesis of activated HSCs is possibly 
mediated through up-regulation of pro-fibrogenic cytokines including TGF-1 and 
CTGF. AT2 receptors generally have divergent pathways compared with AT1 
receptors. Interestingly, it has been predicted that ARB increases levels of 
unbound Ang II after AT1 receptor blockade and subsequently activates AT2 
receptors (Unger, 2002). Therefore, activation of AT2 receptors as well as AT1 
receptor blockade may also contribute to the beneficial effects of ARB. Nabeshima 
et al. reported that liver fibrosis is deteriorated in AT2 receptor-deficient mice 
(Nabeshima et al., 2006). I suppose that AT2 receptor activation also in some 
content contributed to anti-fibrotic effects of ARB in addition to AT1 receptor 
blockade in my present study. 
 As discussed above, some researchers and I concurrently elucidated the 
fibrogenic effects and the molecular mechanism of Ang II in chronic liver disease. 
After our results were published, some new findings about roles of Ang II in 
NASH/NAFLD or liver fibrosis have been reported as following, 1) contribution 
of reactive oxygen species to Ang II-induced liver fibrosis, 2) roles of RAS in the 
development of hepatic steatosis in NASH/NAFLD and 3) clinical trials of ARBs 
in liver fibrosis including NASH/NAFLD patients.  
 Increased oxidative stress is thought to lead to activation of HSCs and 
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liver fibrosis (Koek et al., 2011). Systemic infusion of Ang II to normal or fibrotic 
rats induced activation of HSCs and consequently liver fibrosis mediated through 
increased oxidative stress and pro-inflammatory cytokines (Bataller et al., 2003a, 
2005). Ang II phophorylated p47phox, a subunit of NADPH oxidase, and induced 
reactive oxygen species via NADPH oxidase activity in human HSCs (Bataller et 
al., 2003c). Ang II-induced activation of HSCs was also attenuated by treatment of 
NADPH oxidase inhibitors and HSCs isolated from p47phox-deficient mice showed 
blunted responses to Ang II. Furthermore, p47phox-deficiency attenuated liver 
fibrosis after BDL. Therefore, NADPH oxidase-mediated oxidative stress is 
thought to contribute to Ang II-induced activation of HSCs and development of 
liver fibrosis.  
 In summary, AT1 receptor blockade reduced activated HSCs and prevented 
progression of liver fibrosis in vivo, and Ang II stimulated proliferation and 
collagen synthesis in activated HSCs in vitro possibly through increased 
production of TGF-1 and CTGF (summarized in Figure 28; page 106). These 
results demonstrate that Ang II plays an important role in the progression of liver 
fibrosis in NASH. 
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General Discussion 
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Since the publication of my research, the involvement of RAS including Ang II in 
metabolic disorders has been reported (Putnam et al., 2012). Liver-specific 
disruption of AT1 receptors or ARBs have been shown to attenuate triglyceride 
accumulation in the liver and in turn inflammation and fibrosis in NASH models 
including MCD models, indicating contribution of Ang II to hepatic steatosis in 
NASH/NAFLD concerned with insulin resistance (Fujita et al., 2007; Hirose et al., 
2007; Kurita et al., 2008; Nabeshima et al., 2009). Therefore, the mechanism of 
beneficial effects of AT1 receptor blockade in NASH models is complicated. Some 
mechanisms in Ang II-induced triglyceride accumulation in the liver have been 
proposed including decreased fatty acid oxidation, increased VLDL secretion and 
increased de novo lipogenesis (Ran et al., 2004a, 2004b; Kurita et al., 2008; Rong 
et al., 2010). On the other hand, SCD-1 potently contributes to process of 
lipogenesis and triglyceride synthesis in the liver. Interestingly, Yokozawa et al. 
reported that ARB down-regulates liver SCD-1 expression and ameliorates insulin 
resistance and hepatic steatosis in obese rats (Yokozawa et al., 2009). These 
findings suggest that, in addition to liver fibrosis, Ang II also plays a key role in 
hepatic steatosis, and these effects are possibly mediated through SCD-1 
regulation to some extent. Therefore, Ang II may modulate NASH pathology in 
multiple processes. 
 In my present study, the SCD-1 inhibitor and ARB were used as tool 
compounds to evaluate the roles of SCD-1 and Ang II, respectively. These proteins 
are attractive targets to treat NASH/NAFLD; therefore both compounds may be 
useful to treat NASH/NAFLD. I showed that SCD-1 is related to the early phases 
of NASH. SCD-1 inhibitors may be useful to prevent the onset of NASH in 
patients with simple steatosis or progression of NASH in patients with early 
phases of NASH. In contrast, steatosis, in which SCD-1 activity mainly involved, 
is a trigger to steatohepatitis but the roles in acceleration of disease after the onset 
of NASH are unknown. Therefore, I suppose that the benefit of SCD-1 inhibitors 
are restrictive at advanced stages of patients. In order to confirm the potential of 
SCD-1 inhibitor in advanced stages of patients, it is important to evaluate 
therapeutic protocol in which treatment of the SCD-1 inhibitor is started after 
establishment of the disease in MCD models. Additionally, SCD-1 deficiency 
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developed cutaneous abnormalities and narrow eye fissure with atrophic sebaceous 
and meibomian glands due to defect of lipid synthesis in tissues (Miyazaki et al., 
2001b). SCD-1 also seems to be associated with inflammation in some organs (Liu 
et al., 2011). SCD-1 inhibitor did not cause inflammatory observation; however 
other compounds with more potent systemic inhibition of SCD-1 increased white 
blood cell (Uto et al., 2011). Therefore, liver-specific inhibition may be important 
to avoid these adverse effects.  
 My studies as well as other groups showed beneficial effects of ARBs in 
animal models with chronic liver disease. Furthermore, as discussed above, Ang II 
possibly contributes to hepatic steatosis and other metabolic disorders in addition 
to liver fibrosis. Therefore, ARBs might be useful to treat patients with broad 
stages in NASH/NAFLD such as early steatotic or advanced fibrotic stages. Since 
the publication of our findings, some clinical trials of ARBs in treatment of liver 
fibrosis including NASH patients have been reported (Yokohama et al., 2004, 
2006; Georgescu et al., 2009; Fogari et al., 2012). These studies showed possible 
beneficial effects of ARBs on inflammation, liver injury and metabolic disorders 
in NASH patients. However, they were all small size scale and clinical endpoints 
(histology, serum markes, etc.) and the study designs (duration of treatment, 
severity of patients, etc.) were quite different among studies. Furthermore, only 
few trials showed a reduction of fibrosis, the most important pathology of NASH, 
in histological evaluation with liver biopsy. I think that in order to fully elucidate 
the benefit of ARBs in NASH patients, large scale and placebo-controlled trials 
with long-term histological evaluation are needed. ARBs are highly safe and 
widely treated in the world. If the benefits of ARBs are established in large scale 
clinical trials, these will provide promising treatment of NASH/NAFLD. 
 In conclusion, I demonstrated that SCD-1 plays an important role in the 
onset phase of NASH, and Ang II in the progression of liver fibrosis (summarized 
in Figure 29; page 117).  
  
51 
 
 
 
 
 
 
 
 
Acknowledgements 
 
 
 
  
52 
 
I am deeply grateful to Prof. Tomoki Chiba (Univ. of Tsukuba) for his guidance 
and encouragement throughout the course of my research and doctoral thesis.  
 
I would like to express my gratitude to Prof. Hideko Urushihara (Univ. of 
Tsukuba), Prof. Kouji Nakamura (Univ. of Tsukuba) and Assoc. Prof. Kazuichi 
Sakamoto (Univ. of Tsukuba) for helpful advice and comments to my research and 
thesis.  
 
I would like to express my gratitude to Dr. Ryuta Koishi (Daiichi Sankyo Co., Ltd), 
Dr. Takashi Fukuoka (DS) and Dr. Fujio Isono (DS) for tremendous support and 
encouragement for my study in doctoral course.  
 
I also wish to thank Dr. Toshiyuki Takagi (DS), Ms. Satoko Wakimoto (DS), Dr. 
Yoshikazu Uto (DS), Mr. Hideki Terashima (DS), Dr. Keita Kono (DS), Dr. 
Tsuneaki Ogata (DS), Dr. Jun Ohsumi (DS), Ms. Miwa Suga, Ms. Shoko Honzumi 
(DS), Mr. Keisuke Yamada (DS) and Mr. Hirokazu Ishikawa (Daiichi Sankyo RD 
Novare Co., Ltd) for significant contribution in my research, helpful advice and 
discussion, Ms. Yuko Ueno (DS) and Dr. Yohei Kiyotsuka (DS) for synthesizing 
and providing compound A, Dr. Tomohiro Nishizawa (DS), Ms. Nobumi Nagaoka 
(DS), Ms. Yuka Morikawa (DS), Dr. Fumihiko Matsuda (DS), Dr. Atsuhiro 
Sugidachi (DS) for enormous help and support in my research, and Mr. Haruki 
Domon (DS), Ms. Noriko Kobayashi (DS), Dr. Katsuhiko Nawa (DS), Ms. Yuko 
Ozawa (DS) and all members of Venture Science Laboratories in Daiichi Sankyo 
Co., Ltd for various support during my doctoral course.  
 
I would like to express the deepest appreciation to Daiichi Sankyo Co., Ltd for 
financial support. 
 
Finally, I also want to thank all my friends, co-workers and family. 
 
  
53 
 
 
 
 
 
 
 
 
References 
 
 
  
54 
 
Bataller R, Ginès P, Nicolás JM, Görbig MN, Garcia-Ramallo E, Gasull X, Bosch 
J, Arroyo V, Rodés J (2000). Angiotensin II induces contraction and proliferation 
of human hepatic stellate cells. Gastroenterology, 118, 1149-1156. 
 
Bataller R, Gabele E, Schoonhoven R, Morris T, Lehnert M, Yang L, Brenner DA, 
Rippe RA (2003a). Prolonged infusion of angiotensin II into normal rats induces 
stellate cell activation and proinflammatory events in liver. Am J Physiol 
Gastrointest Liver Physiol, 285, G642–G651. 
 
Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, Colmenero J, 
Nicolás JM, Jiménez W, Weich N, Gutiérrez-Ramos JC, Arroyo V, Rodés J (2003b). 
Activated human hepatic stellate cells express the renin-angiotensin system and 
synthesize angiotensin II. Gastroenterology, 125, 117–125. 
 
Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, 
Schoonhoven R, Hagedorn CH, Lemasters JJ, Brenner DA. (2003c). NADPH 
oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in 
hepatic fibrosis. J Clin Invest, 112, 1383–1394. 
 
Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, 
Rippe RA (2005). Systemic infusion of angiotensin II exacerbates liver fibrosis in 
bile duct-ligated rats. Hepatology, 41, 1046–1055. 
 
Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, 
Gastaldelli A, Tio F, Pulcini J, Berria R, Ma JZ, Dwivedi S, Havranek R, Fincke C, 
DeFronzo R, Bannayan GA, Schenker S, Cusi K (2006). A placebo controlled trial 
of pioglitazone in subjects with nonalcoholic steatohepatitis. N Eng J Med, 355, 
15–25. 
 
Bissell DM, Wang SS, Jarnagin WR, Roll FJ (1995). Cell-specific expression of 
transforming growth factor-beta in rat liver. Evidence for autocrine regulation of 
hepatocyte proliferation. J Clin Invest, 96, 447-455. 
55 
 
 
Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, 
Weiskirchen R (2007). Pro-fibrogenic potential of PDGF-D in liver fibrosis. J 
Hepatol, 46, 1064-74. 
 
Brewster UC, Setaro JF, Perazella MA (2003). The renin–angiotensin–aldosterone 
system: cardiorenal effects and implications for renal and cardiovascular disease 
states. Am J Med Sci, 326, 15–24. 
 
Brilla CG (2000). Renin-angiotensin-aldosterone system and myocardial fibrosis. 
Cardiovasc Res, 47, 1-3. 
 
Buqué X, Martínez MJ, Cano A, Miquilena-Colina ME, García-Monzón C, 
Aspichueta P, Ochoa B (2010). A subset of dysregulated metabolic and survival 
genes is associated with severity of hepatic steatosis in obese Zucker rats. J Lipid 
Res, 51, 500-513. 
 
Chen G, Liang G, Ou J, Goldstein JL, Brown MS (2004). Central role for liver X 
receptor in insulin-mediated activation of Srebp-1c transcription and stimulation 
of fatty acid synthesis in liver. PNAS, 101, 11245-11250. 
 
Czaja MJ, Geerts A, Xu J, Schmiedeberg P, Ju Y (1994). Monocyte 
chemoattractant protein 1 (MCP-1) expression occurs in toxic rat liver injury and 
human liver disease. J Leukoc Biol, 55, 120-126. 
 
Day CP, James OF (1998). Steatohepatitis: A tale of two “hits”? Gastroenterology, 
114, 842-845. 
 
Donnelly KL, Smith CI, Scwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005). 
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with 
nonalcoholic fatty liver disease. J Clin Invest, 115, 1343-1351. 
 
56 
 
Eitel K, Staiger H, Brendel MD, Brandhorst D, Bretzel RG, Haring HU, Kellerer 
M (2002). Different role of saturated and unsaturated fatty acids in beta-cell 
apoptosis. Biochem Biophys Res Commun, 299, 853–856. 
 
Fan JG, Qiao L (2009). Commonly used animal models of non-alcoholic 
steatohepatitis. Hepatobilliary Pancreat Dis Int, 8, 233-240. 
 
Farrell GC, Larter CZ (2006). Nonalcoholic fatty liver disease: from steatosis to 
cirrhosis. Hepatology, 43, S99-S112. 
 
Festi D, Schiumerini R, Marzi L, Di Biase AR, Mandolesi D, Montrone L, Scaioli 
E, Bonato G, Marchesini-Reggiani G, Colecchia A (2013). Review article: the 
diagnosis of non-alcoholic fatty liver disease – availability and accuracy of 
non-invasive methods. Aliment Pharmacol Ther, 37, 392–400. 
 
Flowers MT, Groen AK, Oler AT, Keller MP, Choi Y, Schueler KL, Richards OC, 
Lan H, Miyazaki M, Kuipers F, Kendziorski CM, Ntambi JM, Attie AD (2006). 
Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, 
high-carbohydrate diet. J Lipid Res, 47, 2668-80. 
 
Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski C, Ntambi JM, Attie AD 
(2008). Liver gene expression analysis reveals endoplasmic reticulum stress and 
metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol 
Genomics, 33, 361-72. 
 
Flowers MT, Ade L, Strable MS, Ntambi JM (2012). Combined deletion of SCD1 
from adipose tissue and liver does not protect mice from obesity. J Lipid Res, 53, 
1646-53. 
 
  
57 
 
Fogari R, Maffioli P, Mugellini A, Zoppi A, Lazzari P, Derosa G (2012). Effects of 
losartan and amlodipine alone or combined with simvastatin in hypertensive 
patients with nonalcoholic hepatic steatosis. Eur J Gastroenterol Hepatol, 24, 
164–171. 
 
Friedman SL (2008). Hepatic stellate cells: protean, multifunctional, and 
enigmatic cells of the liver. Physiol Rev, 88, 125–172. 
 
Fujita K, Yoneda M, Wada K, Mawatari H, Takahashi H, Kirikoshi H, Inamori M, 
Nozaki Y, Maeyama S, Saito S, Iwasaki T, Terauchi Y, Nakajima A (2007). 
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of 
nonalcoholic steatohepatitis in rats. Dig Dis Sci, 52, 3455–3464. 
 
George J, Roulot D, Koteliansky VE, Bissell DM (1999). In vivo inhibition of rat 
stellate cell activation by soluble transforming growth factor β type II receptor: a 
potential new therapy for hepatic fibrosis. PNAS, 96, 12719-12724. 
 
Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L (2009). 
Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension 
associated non-alcoholic steatohepatitis. World J Gastroenterol, 15, 942–954. 
 
Gomez-Dominguez E, Gisbert JP, Moreno-Monteagudo JA, Garcia-Buey L, 
Moreno-Otero R (2006). A pilot study of atorvastatin in dyslipidemic, 
non-alcoholic fatty liver patients. Aliment Pharmacol Ther, 23, 1643-1647. 
 
Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, 
Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Järvinen H (2008). Gene 
expression in human NAFLD. Am J Physiol Gastroenterol Liver Physiol, 294, 
G1281-1287. 
 
Gressner AM (1995). Cytokines and cellular crosstalk involved in the activation of 
fat-storing cells. J Hepatol, 22 Suppl, 28-36. 
58 
 
 
Harrison SA, Ramrakhiani S, Brunt EM, Anabari MA, Cortese C, Bacon BR 
(2003a). Orlistat in the treatment of NASH: a case series. Am J Gasteroenterol, 98, 
926-930. 
 
Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S (2003b). Vitamin E and 
C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J 
Gastroenterol, 98, 2485–2490. 
 
Hernandez-Gea V, Friedman SL (2011). Pathogenesis of liver fibrosis. Annu Rev 
Pathol Mech Dis, 6, 425-456. 
 
Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, Yoshioka A, Takahashi M, 
Akisawa N, Iwasaki S, Oben JA, Onishi S (2007). Angiotensin II type 1 receptor 
blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology, 45, 1375–
1381. 
 
Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S (1995). Angiotensin II 
receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by 
unilateral ureteral obstruction. Kidney Int, 47, 1285-1294. 
 
Issandou M, Bouilot A, Brusq JM, Forest MC, Grillot D, Guillard R, Martin S, 
Michiels C, Sulpice T, Daugan A (2009). Pharmacological inhibition of 
stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat 
models. Eur J Pharmacol, 618, 28-36. 
 
Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie 
DM, Powell EE (2001). Angiotensin-converting enzyme inhibition attenuates the 
progression of rat hepatic fibrosis. Gastroenterology, 121, 148-155. 
 
  
59 
 
Kagami S, Border WA, Miller DE, Noble NA (1994). Angiotensin II stimulates 
extracellular matrix protein synthesis through induction of transforming growth 
factor-beta expression in rat glomerular mesangial cells. J Clin Invest, 93, 
2431-2437. 
 
Kawada N, Seki S, Inoue M, Kuroki T (1998). Effect of antioxidants, resveratrol, 
quercetin, and N-acetylcysteine, on the functions of cultured rat hepatic stellate 
cells and Kupffer cells. Hepatology, 27, 1265-1274. 
 
Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Ishimura 
Y, Chatani F, Iwao H (1995). Angiotensin II type 1 receptor antagonist inhibits the 
gene expression of transforming growth factor-β1 and extracellular matrix in 
cardiac and vascular tissues of hypertensive rats. J Pharmacol Exp Ther, 273, 
509-515. 
 
Koek GH, Liedorp PR, Bast A (2011). The role of oxidative stress in non-alcoholic 
steatohepatitis. Clin Chim Acta, 412, 1297-305. 
 
Koltun DO, Vasilevich NI, Parkhill EQ, Glushkov AI, Zilbershtein TM, 
Mayboroda EI, Boze MA, Cole AG, Henderson I, Zautke NA, Brunn SA, Chu N, 
Hao J, Mollova N, Leung K, Chisholm JW, Zablocki J (2009). Orally bioavailable, 
liver-selective stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett, 
19, 3050-3. 
 
Kotronen A, Seppanen-Laakso T, Westerbacka J, Kiviluoto T, Arola J, Ruskeepaa 
AL, Oresic M, Yki-Jarvinen H (2009). Hepatic stearoyl-CoA desaturase (SCD)-1 
activity and diacylglycerol but not ceramide concentrations are increased in the 
nonalcoholic human fatty liver. Diabetes, 58, 203-208. 
 
Kountouras J, Billing BH, Scheuer PJ (1984). Prolonged bile duct obstruction: a 
new experimental model for cirrhosis in the rat. Br J Exp Path, 65, 305-311. 
 
60 
 
Kurita S, Takamura T, Ota T, Matsuzawa-Nagata N, Kita Y, Uno M, Nabemoto S, 
Ishikura K, Misu H, Ando H, Zen Y, Nakanuma Y, Kaneko S (2008). Olmesartan 
ameliorates a dietary rat model of non-alcoholic steatohepatitis through its 
pleiotropic effects. Eur J Pharmacol, 588, 316–324. 
 
Larter CZ, Yeh MM, Haigh WG, Williams J, Brown S, Bell-Anderson KS, Lee SP, 
Farrell GC (2008). Hepatic free fatty acids accumulate in experimental 
steatohepatitis: role of adaptive pathways. J Hepatol, 48, 638-647. 
 
Leask A, Holmes A, Abraham DJ (2002). Connective tissue growth factor: a new 
and important player in the pathogenesis of fibrosis. Curr. Pheumatol Rep, 4, 
136-142. 
 
Lewis GF, Carpentier A, Adeli K, Giacca A (2002). Disordered fat storage and 
mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr 
Rev, 23, 201-229. 
 
Li Z, Berk M, Mclntyre TM, Feldstein AE (2009). Hepatic lipid partitioning and 
liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J 
Biol Chem, 284, 5637-5644. 
 
Liu X, Strable MS, Ntambi JM (2011). Stearoyl CoA desaturase 1: role in cellular 
inflammation and stress. Adv Nutr, 2, 15-22. 
 
Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ (2007). Free fatty acids 
sensitize hepatocytes to TRAIL mediated cytotoxicity. Gut, 56, 1124-1131. 
 
Malinowski SS, Byrd JS, Bell AM, Wofford MR, Riche DM (2013). 
Pharmacologic therapy for nonalcoholic fatty liver disease in adults. 
Pharmacotherapy, 33, 223–242. 
 
61 
 
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N (2001). 
Metformin in non-alcoholic steatohepatitis. Lancet, 358, 893-894. 
 
Marra F, Valente AJ, Pinzani M, Abboud HE (1993). Cultured human liver fat 
storing cells produce monocyte chemotactic protein-1: regulation by 
proinflammatory cytokines. J Clin Invest, 92, 1674-1680. 
 
Marra F, Romanelli RG, Giannini C, Failli P, Pastacaldi S, Arrighi MC, Pinzani M, 
Laffi G, Montalto P, Gentilini P (1999). Monocyte chemotactic protein-1 as a 
chemoattractant for human hepatic stellate cells. Hepatology, 29, 140-148. 
 
Matsuoka M, Tsukamoto H (1990). Stimulation of hepatic lipocyte collagen 
production by Kuppfer cell-derived transforming growth factor β: implications for 
a pathogenetic role in alcoholic liver fibrogenesis. Hepatology, 11, 599-605. 
 
Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, 
Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S (2007). Lipid-induced 
oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology, 
46, 1392-1403. 
 
Mehta PK, Griendling KK (2007). Angiotensin II cell signaling: physiological and 
pathological effects in the cardiovascular system. Am J Physiol Cell Physiol, 292, 
C82–C97. 
 
Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM (2000). The 
biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice 
with a disruption of the gene for stearoyl-CoA desaturase 1. J Biol Chem, 275, 
30132-30138. 
 
  
62 
 
Miyazaki M, Kim YC, Ntambi JM (2001a). A lipogenic diet in mice with a 
disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of 
endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res, 42, 
1018-1024. 
 
Miyazaki M, Man WC, Ntambi JM (2001b). Targeted disruption of stearoyl-CoA 
desaturase1 gene in mice causes atrophy of sebaceous and meibomian glands and 
depletion of wax esters in the eyelid. J Nutr, 131, 2260–8. 
 
Miyazaki M, Dobrzyn A, Man WC, Chu K, Sampath H, Kim HJ, Ntambi JM 
(2004). Stearoyl-CoA desaturase 1 gene expression is necessary for 
fructose-mediated induction of lipogenic gene expression by sterol regulatory 
element-binding protein-1c-dependent and –independent mechanisms. J Biol 
Chem, 279, 25164-25171. 
 
Miyazaki M, Flowers MT, Sampath H, Chu K, Otzelberger C, Liu X, Ntambi JM 
(2007). Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from 
carbohydrate-induced adiposity and hepatic steatosis. Cell Metab, 6, 484-496. 
 
Mizuno M, Sada T, Ikeda M, Fukuda N, Miyamoto M, Yanagisawa H, Koike H 
(1995). Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor 
antagonist. Eur J Pharmacol, 285, 181-188. 
 
Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, Wolfe LF, 
Brizio-Molteni L, Veno P (2000). Control of radiation-induced pneumopathy and 
lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II 
type 1 receptor blocker. Int J Radiat Biol, 76, 523-532. 
 
Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Iwai M, Horiuchi M, Chayama K 
(2006). Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced 
liver fibrosis. Biochem Biophys Res Commun. 346, 658–664. 
 
63 
 
Nabeshima Y, Tazuma S, Kanno K, Hyogo H, Chayama K (2009). Deletion of 
angiotensin II type I receptor reduces hepatic steatosis. J Hepatol, 50, 1226–1235. 
 
Ntambi JM (1995). The regulation of stearoyl-CoA desaturase (SCD). Prog Lipid 
Res, 34, 139-150. 
 
Ntambi JM, Miyazaki M, Stoehr JP, Lan H, Kendziorski CM, Yandell BS, Song Y, 
Cohen P, Friedman JM, Attie AD (2002). Loss of stearoyl-CoA desaturase-1 
function protects mice against adiposity. PNAS, 99, 11482-11486. 
 
Ohishi T, Saito H, Tsusaka K, Toda K, Inagaki H, Hamada Y, Kumagai N, 
Atsukawa K, Ishii H (2001). Anti-fibrogenic effect of an angiotensin converting 
enzyme inhibitor on chronic carbon tetrachloride-induced hepatic fibrosis in rats. 
Hepatol Res, 21, 147-158. 
 
Paizis G, Gilbert RE, Cooper ME, Murthi P, Schembri JM, Wu LL, Rumble JR, 
Kelly DJ, Tikellis C, Cox A, Smallwood RA, Angus PW (2001). Effect of 
angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. J 
Hepatol, 35, 376-385. 
 
Paizis G, Cooper ME, Schembri JM, Tikellis C, Burrell LM, Angus PW (2002). 
Up-regulation of components of the rennin-angiotensin system in the bile 
duct-ligated rat liver. Gastroenterology, 123, 1667-1676. 
 
Paradis V, Dargere D, Vidaud M, De Gouville AC, Huet S, Martinez V, Gauthier 
JM, Ba N, Sobesky R, Ratziu V, Bedossa P (1999). Expression of connective tissue 
growth factor in experimental rat and human liver fibrosis. Hepatology, 30, 
968-976. 
 
Paradis V, Dargere D, Bonvoust F, Vidaud M, Segarini P, Bedossa P (2002). 
Effects and regulation of connective tissue growth factor on hepatic stellate cells. 
Lab Invest, 82, 767-773. 
64 
 
 
Paul M, Royan MA, Kreutz R (2006). Physiology of local renin-angiotensin 
systems. Physiol Rev, 86, 747-803. 
 
Peter S (2011). Animal models for the study of hepatic fibrosis. Best Prac Res Clin 
Gastroenterol, 25, 319-333. 
 
Pinzani M (2002). PDGF and signal transduction in hepatic stellate cells. Front 
Biosci, 7, d1720-6. 
 
Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhery J, Cheung O, Sargeant C, 
Contos MJ, Sanyal AJ (2007). A lipidomic analysis of nonalcoholic fatty liver 
disease. Hepatology, 46, 1081-1090. 
 
Putnam K, Shoemaker R, Yiannikouris Y, Cassis LA (2012). The renin-angiotensin 
system: a target of and contributor to dyslipidemias, altered glucose homeostasis, 
and hypertension of the metabolic syndrome. Am J Physiol Heart Circ Physiol, 
302, H1219-30. 
 
Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H (1999). Blockade of type β 
transforming growth factor signaling prevents liver fibrosis and dysfunction in the 
rat. PNAS, 96, 2345-2349. 
 
Rahman SM, Dobrzyn A, Dobrzyn P, Lee SH, Miyazaki M, Ntambi JM (2003). 
Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and 
down-regulates protein-tyrosine phosphatase 1B in muscle. PNAS, 100, 
11110-11115. 
 
Rahman SM, Dobrzyn A, Lee SH, Dobrzyn P, Miyazaki M, Ntambi JM (2005). 
Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen 
accumulation in brown adipose tissue. Am J Physiol Endocrinol Metab, 288, 
E381-E387. 
65 
 
 
Ramos SG, Montenegro AP, Goissis G, Rossi MA (1994). Captopril reduces 
collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver 
fibrosis. Pathol Int, 44, 655-661. 
 
Ramtohul YK, Black C, Chan CC, Crane S, Guay J, Guiral S, Huang Z, Oballa R, 
Xu LJ, Zhang L, Li CS (2010). SAR and optimization of thiazole analogs as potent 
stearoyl-CoA desaturase inhibitors. Bioorg Med Chem Lett, 20, 1593-7. 
 
Ran J, Hirano T, Adachi M (2004a). Angiotensin II type 1 receptor blocker 
ameliorates overproduction and accumulation of triglyceride in the liver of Zucker 
fatty rats. Am J Physiol Endocrinol Metab, 287, E227–E232. 
 
Ran J, Hirano T, Adachi M (2004b). Chronic ANG II infusion increases plasma 
triglyceride level by stimulating hepatic triglyceride production in rats. Am J 
Physiol Endocrinol Metab, 287, E955–E961. 
 
Ray PE, Aguilera G, Kopp JB, Horikoshi S, Klotman PE (1991). Angiotensin II 
receptor-mediated proliferation of cultured human fetal mesangial cells. Kidney 
Int, 40, 764-771. 
 
Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM (2008). 
Mechanisms of hepatic steatosis in mice fed a lipogenic methionine 
choline-deficient diet. J Lipid Res, 49, 1068-1076. 
 
Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, Ng RK, Turner SM, Badger TM, 
Pitas RE, Maher JJ (2006). Mice fed a lipogenic methionine-choline-deficient diet 
develop hypermetabolism coincident with hapatic suppresion of SCD-1. J Lipid 
Res, 47, 2280-2290. 
 
  
66 
 
Rong X, Li Y, Ebihara K, Zhao M, Kusakabe T, Tomita T, Murray M, Nakao K 
(2010). Irbesartan treatment up-regulates hepatic expression of PPARalpha and its 
target genes in obese Koletsky (fa(k)/fa(k)) rats: a link to amelioration of 
hypertriglyceridaemia. Br J Pharmacol, 160, 1796–1807. 
 
Sampath H, Flowers MT, Liu X, Paton CM, Sullivan R, Chu K, Zhao M, Ntambi 
JM (2009). Skin-specific deletion of stearoyl-CoA desaturase-1 alters skin lipid 
composition and protects mice from high fat diet-induced obesity. J Biol Chem, 
284, 19961-73. 
 
Sampath H, Ntambi JM (2011). The role of stearoyl-CoA desaturase in obesity, 
insulin resistance and inflammation. Ann NY Acad Sci, 1243, 47-53. 
 
Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, 
Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, 
Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; NASH CRN (2010). 
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med, 
362, 1675–1685. 
 
Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK (2006). Beneficial 
effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in 
patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol, 22, 634–638. 
 
Schneider AW, Kalk JF, Klein CP (1999). Effect of losartan, an angiotensin II 
receptor antagonist, on portal pressure in cirrhosis. Hepatology, 29, 334-339. 
 
Sun Y, Zhang J, Zhang JQ, Ramires FJ (2000). Local angiotensin II and 
transforming growth factor beta1 in renal fibrosis of rats. Hypertension, 35, 
1078-1084. 
 
67 
 
Terashima H, Kato M, Yasumo H, Tsuchida H, Mizuno M, Sada T (2010). A 
sensitive short-term evaluation of antifibrotic effects using newly established type 
I collagen reporter transgenic rats. Am J Physiol, 299, F792-F801. 
 
Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC (2000). Angiotensin II 
activates collagen I gene through a mechanism involving the MAP/ER kinase 
pathway. Hypertension, 36, 330-336. 
 
Torres DM, Harrison SA (2008). Diagnosis and therapy of nonalcoholic 
steatohepatitis. Gastroenterology, 134, 1682-1698. 
 
Trauner M, Arrese M, Wagner M (2010). Fatty liver and lipotoxicity. Biochim 
Biophys Acta, 1801, 299-310. 
 
Unger T (2002). The role of the renin–angiotensin system in the development of 
cardiovascular disease. Am J Cardiol, 89, 3A–9A. 
 
Uto Y, Ogata T, Kiyotsuka Y, Ueno Y, Miyazawa Y, Kurata H, Deguchi T, 
Watanabe N, Konishi M, Okuyama R, Kurikawa N, Takagi T, Wakimoto S, Osumi 
J (2010). Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: 
Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl] pyridazine-3-carboxylic 
acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering 
effects in Zucker fatty rats. Bioorg Med Chem Lett, 20, 341-345. 
 
Uto Y, Ogata T, Konishi M, Ueno Y, Kiyotsuka Y, Miyazawa Y, Kurata H, Ohsumi 
J. 2011年 5月 23日. 日本ケミカルバイオロジー学会第 6 回年会. P-068; 
Benzoylpiperidine-based SCD inhibitors as lipid metabolism modulators. 
 
Weber H, Taylor DS, Molloy CJ (1994). Angiotensin II induces delayed 
mitogenesis and cellular proliferation in rat aortic smooth muscle cells. J Clin 
Invest, 93, 788-798. 
 
68 
 
Weber KT (1997). Fibrosis, a common pathway to organ failure: angiotensin II and 
tissue repair. Semin Nephrol, 17, 467-491. 
 
Williams EJ, Gaça MD, Brigstock DR, Arthur MJ, Benyon RC (2000). Increased 
expression of connective tissue growth factor in fibrotic human liver and in 
activated hepatic stellate cells. J Hepatol, 32, 754-761. 
 
Wolf G, Haberstroh U, Neilson EG (1992). Angiotensin II stimulates the 
proliferation and biosynthesis of type I collagen in cultured murine mesangial 
cells. Am J Pathol, 140, 95-107. 
 
Yata Y, Gotwals P, Koteliansky V, Rockey DC (2002). Dose-dependent inhibition 
of hepatic fibrosis in mice by a TGF-β soluble receptor: implications for 
antifibrotic therapy. Hepatology, 35, 1022-1030. 
 
Yokohama S, Yoneda M, Haneda M, Okamoto S, Okada M, Aso K, Hasegawa T, 
Tokusashi Y, Miyokawa N, Nakamura K (2004). Therapeutic efficacy of an 
angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. 
Hepatology, 40, 1222–1225. 
 
Yokohama S, Tokusashi Y, Nakamura K, Tamaki Y, Okamoto S, Okada M, Aso K, 
Hasegawa T, Aoshima M, Miyokawa N, Haneda M, Yoneda M (2006). Inhibitory 
effect of angiotensin II receptor antagonist on hepatic stellate cell activation in 
non-alcoholic steatohepatitis. World J Gastroenterol, 12, 322–326. 
 
Yokozawa J, Sasaki T, Ohwada K, Sasaki Y, Ito JI, Saito T, Kawata S (2009). 
Down-regulation of hepatic stearoyl-CoA desaturase 1 expression by angiotensin 
II receptor blocker in the obese fa/fa Zucker rat: possible role in amelioration of 
insulin resistance and hepatic steatosis. J Gastroenterol, 44, 583–591. 
 
69 
 
Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, 
Fukui H (2001). Angiotensin-II type 1 receptor interaction is a major regulator for 
liver fibrosis development in rats. Hepatology, 34, 745-750. 
 
Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, 
Yanase K, Kuriyama S, Fukui H (2002). Inhibition of rennin-angiotensin system 
attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in 
rats. J Hepatol, 37, 22-30. 
 
Younossi ZM, Diehl AM, Ong JP (2002). Nonalcoholic fatty liver disease: an 
agenda for clinical research. Hepatology, 35, 746-752. 
 
Zhang S, Wang J, Liu Q, Harnish DC (2009). Farnesoid X receptor agonist 
WAY-362450 attenuates liver inflammation and fibrosis in murine model of 
non-alcoholic steatohepatitis. J Hepatol, 51, 380-388. 
 
  
70 
 
 
 
 
 
 
 
Tables 
 
 
  
71 
 
 
 
 
 
 
 
Table 1  Sequences of primers and probes used in real-time PCR analysis 
 
The sequences of primers and probes for each gene used in present study are indicated. FAM; 
6-carboxyfluorescein, TAMRA; 6-carboxytetramethylrhodamine. 
  
Collagen 1a1
Forward primer 5'-CTCCCAGCGGTGGTTATGAC-3'
Reverse primer 5'-TGCTGGCTCAGGCTCTTGA-3'
Probe 5'-FAM -AAGATGGTGGCCGTTACTACCGGGC-TAMRA -3'
-Smooth muscle actin (-SMA)
Forward primer 5'-CAACTGGTATTGTGCTGGACTCTG-3'
Reverse primer 5'-CTCCTTGATGTCACGGACGATCT-3'
Probe 5'-FAM -AGATGGCGTGACTCACAACGTGCCT-TAMRA -3'
Connective tissue growth factor (CTGF)
Forward primer 5'-CAATACCTTCTGCAGGCTGGA-3'
Reverse primer 5'-TTAGCCCGGTAGGTCTTCACA-3'
Probe 5'-FAM -TGCATCCGGACGCCTAAAATTGCCA-TAMRA -3'
Monocyte chemotactic protein-1 (MCP-1)
Forward primer 5'-CTTCACAGTTGCTGCCTGTAGC-3'
Reverse primer 5'-AGTGAATGAGTAGCAGCAGGTGAG-3'
Probe 5'-FAM -TGTCTCAGCCAGATGCAGTTAATGCCC-TAMRA -3'
Stearoyl-CoA desaturase-1 (SCD-1)
Forward primer 5'-CCGCTGGCACATCAACTTCA-3'
Reverse primer 5'-AAACTTTTTTCCGGTCGTAAGCC-3'
Probe 5'-FAM -CACGTTCTTCATCGACTGCATGGCTG-TAMRA -3'
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Table 2  Effects of an SCD-1 Inhibitor on body weight and liver weight of MCD 
rats 
 
Rats were treated as shown in Materials and Methods. Control, vehicle-treated rats 
fed with control diets (n = 4); MCD, vehicle-treated rats fed with MCD diets 
(n = 8); compound A (30 and 100 mg/kg/day) was administered daily to rats fed 
with MCD diets (n = 5 and 4, respectively). Body weight was measured before and 
at 8 weeks after the first treatment, and body weight gain was calculated. Livers 
were removed and weighed at 8 weeks after the first treatment. Values are Means ± 
SE. ** p < 0.01 vs. control (by t-test). 
  
Body weight gain (g) 9.6 ± 5.6 -76.4 ± 2.6** -80.8 ± 5.1 -89.4 ± 4.3
Liver weight (g) 9.41 ± 0.08 6.56 ± 0.23** 6.35 ± 0.4 6.17 ± 0.22
Liver weight
(g/100 g of body weight) 3.57 ± 0.06 3.59 ± 0.08 3.64 ± 0.18 3.74 ± 0.08
Control MCD 30 100
Compound A (mg/kg)
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Table 3  Comparison of MCD and BDL models 
 
MCD; methionine and choline-deficient, BDL; bile duct ligation 
 
  
Metabolic
disorders
Hepatic
steatosis
Liver injury
Inflammation
Fibrosis
MCD model
Fatty liver-
based NASH
models
Yes Yes Yes Yes
BDL model Pure fibrosis
models
No No Yes Yes
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Table 4  Effects of ARB on survival rate, final body weight and liver weight 
 
Rats were treated as described in Materials and Methods. Sham, sham-operated 
rats receiving the vehicle; BDL, bile duct-ligated rats receiving the vehicle; 
BDL+ARB, bile duct ligation followed by 1 mg/kg/day of olmesartan treatment. 
Survival rate was calculated during the treatment of ARB (from Day 7 to Day 21). 
Final body weight and liver were weighed at 3 weeks after surgery. Values are 
Means ± SE. * p < 0.05,** p < 0.01 vs. sham, ## p < 0.01 vs. BDL. 
  
100% 80% 70%
(n = 5) (n = 10) (n = 10)
Final body weight (g) 304 ± 7 275 ± 8* 250 ± 15
Liver weight
(g/100 g of body weight)
3.41 ± 0.07 6.06 ± 0.15** 5.46 ± 0.24##
Sham BDL BDL + ARB
Survival rate
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Figure 1  “Two hit theory” in onset and progression of NASH. NASH is thought 
to develop in a two-step process. The “first hit” is the lipid accumulation in the 
liver, which is caused by obesity, insulin resistance and other metabolic disorders. 
Subsequently the “second hit” stimuli lead to liver injury, inflammation and 
fibrosis. 
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Figure 2  Regulation of lipid content in liver. Liver lipid levels were regulated by 
four mechanisms as shown in (1) to (4). In NASH/NAFLD patients, (1) and (2) are 
generally up-regulated. FFA: fatty acid, TG; triglyceride, VLDL; very low density 
lipoprotein 
  
FFA TG
(1) De novo fatty acid synthesis 
(lipogenesis)
(2) Fatty acid uptake
（influx）
 -oxidation
(3) Secretion from 
liver as VLDL
SCD-1
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Figure 3  Structure of an SCD-1 inhibitor, compound A. 
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Figure 4  Effects of compound A on SCD-1 activity (A) and triglyceride levels 
(B) in the liver of mice fed with lipogenic diets. (A) Compound A was 
administered once at doses of 10, 30 and 100 mg/kg to mice fed with lipogenic 
diets (n = 2). Liver SCD-1 activity was measured as shown in Materials and 
Methods. (B) Compound A was administered once-daily for 7 days at doses of 10, 
30 and 100 mg/kg to mice fed with lipogenic diets (n = 6). Liver triglyceride 
content was measured as shown in Materials and Methods. Values are Means + SE. 
** p < 0.01 vs. normal diet (by Student’s t-test), ## p < 0.01 vs. lipogenic diets (by 
Dunnett’s test). 
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Figure 5  Luciferase (A) and triglyceride content (B) in the liver of MCD rats. 
Rats were treated as described in Materials and Methods. Control, vehicle-treated 
rats fed with control diets (n = 5 for each time point); MCD, vehicle-treated rats 
fed with MCD diets (n = 5 for each time point). Liver samples were prepared at 
indicated times after starting feeding of MCD diets. Values are Means + SE. 
** p < 0.01 vs. control (by Student’s t-test). 
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Figure 6  Effects of SCD-1 inhibitor on liver triglyceride levels in MCD rats. 
Rats were treated as shown in Materials and Methods. Control, vehicle-treated rats 
fed with control diets (n = 4); MCD, vehicle-treated rats fed with MCD diets 
(n = 8); an SCD-1 inhibitor, compound A (30 and 100 mg/kg/day) was 
administered daily to rats fed with MCD diets (n = 5 and 4, respectively). Livers 
were prepared at 8 weeks after the first treatment. Values are Means + SE. 
** p < 0.01 vs. control (by Student’s t-test), ## p < 0.01 vs. MCD (by Dunnett’s 
test). 
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Figure 7  Effects of SCD-1 inhibitor on plasma AST (A) and ALT (B) levels in 
MCD rats. Rats were treated as shown in Materials and Methods. Control, 
vehicle-treated rats fed with control diets (n = 4); MCD, vehicle-treated rats fed 
with MCD diets (n = 8); an SCD-1 inhibitor, compound A (30 and 100 mg/kg/day) 
was administered daily to rats fed with MCD diets (n = 5 and 4, respectively). 
Plasma samples were prepared at 8 weeks after the first treatment. Values are 
Means + SE. ** p < 0.01 vs. control (Student’s t-test), # p < 0.05, ## p < 0.01 vs. 
MCD (Dunnett’s test). 
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(Figure 8) 
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Figure 8  Histological analysis of liver of SCD-1 inhibitor-treated MCD rats. 
Rats were treated as shown in Materials and Methods. (A) Control, vehicle-treated 
rats fed with control diets; (B) and (E) MCD, vehicle-treated rats fed with MCD 
diets; (C) an SCD-1 inhibitor, compound A 30 mg/kg/day; (D) and (F) compound 
A 100 mg/kg/day; compound A was administered daily to rats fed with MCD diets. 
Liver sections were prepared at 8 weeks after the first treatment, and performed by 
hematoxylin-eosin staining. Representative sections of rats in each group are 
shown. Arrows indicate inflammatory cell infiltration. Scale of bars in (A) to (D) 
indicate 0.4 mm and 0.1 mm in (E) and (F). 
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Figure 9  The scores of hepatocellular degeneration (A) and inflammation (B) in 
the liver of SCD-1 inhibitor-treated MCD rats. Rats were treated as shown in 
Materials and Methods. Control, vehicle-treated rats fed with control diets (n = 4); 
MCD, vehicle-treated rats fed with MCD diets (n = 8); an SCD-1 inhibitor, 
compound A (30 and 100 mg/kg/day) was administered daily to rats fed with MCD 
diets (n = 5 and 4, respectively). Liver sections were prepared at 8 weeks after the 
first treatment, and performed by hematoxylin-eosin staining. The degree of 
hepatocellular degeneration and inflammation were scored as follows: 0, none; 1, 
slight; 2, mild; 3, moderate. Inflammation was indicated as the sum (0 to 6) of 
portal inflammation (score: 0 to 3) and lobular inflammation (score: 0 to 3). 
Values are Means + SE * p < 0.05, ** p < 0.01 vs. control (by Student’s t-test), 
# p < 0.05, ## p < 0.01 vs. MCD (by Dunnett’s test). 
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(Figure 10) 
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Figure 10  Masson-trichrome staining of liver in SCD-1 inhibitor-treated MCD 
rats. Rats were treated as shown in Materials and Methods. Control, 
vehicle-treated rats fed with control diets (n = 4); MCD, vehicle-treated rats fed 
with MCD diets (n = 8); an SCD-1 inhibitor, compound A (30 and 100 mg/kg/day) 
was administered daily to rats fed with MCD diets (n = 5 and 4, respectively). 
Liver sections were prepared at 8 weeks after the first treatment, and performed by 
Masson-trichrome staining. Representative sections of rats in MCD (A) and 
compound A 100 mg/kg/day (B) are shown. Fibrotic area is stained as blue. Bar 
indicates 0.4 mm. (C) fibrosis was scored as follows: 1, pericellular and 
perivenular fibrosis; 2, focal bridging fibrosis; 3, bridging fibrosis with lobular 
distortion; 4, cirrhosis. Values are Means + SE. ** p < 0.01 vs. control (by 
Student’s t-test), # p < 0.05, ## p < 0.01 vs. MCD (by Dunnett’s test). 
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Figure 11  Effects of SCD-1 inhibitor on promoter activity of collagen 1a1 (A) 
and hydroxyproline content (B) in the liver of MCD rats. Rats were treated as 
shown in Materials and Methods. Control, vehicle-treated rats fed with control 
diets (n = 4); MCD, vehicle-treated rats fed with MCD diets (n = 8); an SCD-1 
inhibitor, compound A (30 and 100 mg/kg/day) was administered daily to rats fed 
with MCD diets (n = 5 and 4, respectively). Liver samples were prepared at 8 
weeks after the first treatment. Values are Means + SE. All of the data were not 
statistically significant (by Student’s t-test or Dunnett’s test). 
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Figure 12  Effects of SCD-1 inhibitor on mRNA expression of MCP-1 in the 
liver of MCD rats. Rats were treated as shown in Materials and Methods. Control, 
vehicle-treated rats fed with control diets (n = 4); MCD, vehicle-treated rats fed 
with MCD diets (n = 8); an SCD-1 inhibitor, compound A (30 and 100 mg/kg/day) 
was administered daily to rats fed with MCD diets (n = 5 and 4, respectively). 
Liver samples were prepared at 8 weeks after the first treatment. Values are Means 
+ SE. ** p < 0.01 vs. control (by Student’s t-test), # p < 0.05 vs. MCD (by 
Dunnett’s test). 
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Figure 13  Effects of feeding of MCD diets on SCD-1 mRNA expressions in the 
liver of rats. Rats were treated as shown in Materials and Methods. Control, 
vehicle-treated rats fed with control diets (n = 4); MCD, vehicle-treated rats fed 
with MCD diets (n = 8). Liver samples were prepared after 8 weeks feeding of 
MCD diets. Values are Means + SE ** p < 0.01 vs. control (by Student’s t-test). 
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Figure 16  Time course of hydoxyproline content in the liver of BDL rats. Rats 
were treated as described in Materials and Methods. Sham, sham-operated rats 
receiving the vehicle (n = 3 to 5); BDL, bile duct-ligated rats receiving the vehicle 
(n = 3 to 6). Liver samples were prepared at indicated times after surgery. Values 
are Means + SE. * p < 0.05, ** p < 0.01 vs. sham (by Student’s t-test). 
  
0
20
40
60
80
100
120
140
160
180
Week 1 Week 2 Week 3
Li
ve
r h
yd
ro
xy
pr
ol
in
e 
(g
/g
 li
ve
r)
Sham BDL
**
**
*
94 
 
 
 
 
 
 
 
 
 
 
Figure 17  Time course of plasma AST (A) and ALT (B) levels in BDL rats. Rats 
were treated as described in Materials and Methods. Sham, sham-operated rats 
receiving the vehicle (n = 3 to 5); BDL, bile duct-ligated rats receiving the vehicle 
(n = 3 to 6). Plasma samples were prepared at indicated times after surgery. Values 
are Means + SE. ** p < 0.01 vs. sham (by Student’s t-test). 
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Figure 18  Time course of body weight change in BDL rats. Rats were treated as 
described in Materials and Methods. Sham, sham-operated rats receiving the 
vehicle (n = 5); BDL, bile duct-ligated rats receiving the vehicle (n = 5). Values 
are Means ± SE. 
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Figure 19  Effects of ARB on liver hydroxyproline content in BDL rats. Rats 
were treated as described in Materials and Methods. Sham, sham-operated rats 
receiving the vehicle (n = 5); BDL, bile duct-ligated rats receiving the vehicle 
(n = 8); BDL+ARB, bile duct ligation followed by 1 mg/kg/day of olmesartan 
treatment (n = 7). Liver samples were prepared at 3 weeks after surgery. Values are 
Means + SE. ** p < 0.01 vs. sham, # p < 0.05 vs. BDL (by Student’s t-test). 
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Figure 20  Histological analysis of the liver in ARB-treated BDL rats. Liver 
sections were examined by Masson-trichrome staining (A), immunohistochemical 
staining using antibodies against -SMA (B) or AT1 receptor (C). Rats were 
treated as described in Materials and Methods. Sham, sham-operated rats receiving 
the vehicle; BDL, bile duct-ligated rats receiving the vehicle; BDL+ARB, bile 
duct ligation followed by 1 mg/kg/day of olmesartan treatment. Liver samples 
were prepared at 3 weeks after surgery. The three images on the left, in the middle 
and on the right are consecutive. Representative sections of rats in each group are 
shown. Arrowheads indicate the bile duct proliferation. Arrows indicate the site of 
fibrosis (A), the -SMA-positive cells (B) and the AT1-positive cells (C), 
respectively. Original magnification ×25.  
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Figure 21  Effects of ARB on mRNA expression of collagen 1a1 (A) and -SMA 
(B) in the liver of BDL rats. Rats were treated as described in Materials and 
Methods. Sham, sham-operated rats receiving the vehicle (n = 5); BDL, bile 
duct-ligated rats receiving the vehicle (n = 8); BDL+ARB, bile duct ligation 
followed by 1 mg/kg/day of olmesartan treatment (n = 7). Liver samples were 
prepared at 3 weeks after surgery. Values are Means + SE. ** p < 0.01 vs. sham, 
# p < 0.05 vs. BDL (by Student’s t-test). 
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Figure 22  Effects of ARB on plasma TGF-1 levels in BDL rats. Rats were 
treated as described in Materials and Methods. Sham, sham-operated rats receiving 
the vehicle (n = 5); BDL, bile duct-ligated rats receiving the vehicle (n = 8); 
BDL+ARB, bile duct ligation followed by 1 mg/kg/day of olmesartan treatment 
(n = 7). Plasma samples were prepared at 3 weeks after surgery. Values are Means 
+ SE. * p < 0.05 vs. sham, # p < 0.05 vs. BDL (by Student’s t-test). 
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Figure 23 Effects of ARB on plasma AST (A) and ALT (B) levels in BDL 
rats. Rats were treated as described in Materials and Methods. Sham, 
sham-operated rats receiving the vehicle (n = 5); BDL, bile duct-ligated rats 
receiving the vehicle (n = 8); BDL+ARB, bile duct ligation followed by 
1 mg/kg/day of olmesartan treatment (n = 7). Plasma samples were prepared at 3 
weeks after surgery. Values are Means + SE. ** p < 0.01 vs. sham (by Student’s 
t-test). 
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Figure 24  Effects of Ang II and ARB on proliferation in activated HSCs in vitro. 
HSCs were incubated with Ang II in the presence or absence of 10 M RNH-6270 
(ARB) in serum-free medium for 48 hr., and DNA synthesis was measured by 
calculating the amount of incorporated [3H]thymidine into cells, as described in 
Materials and Methods. Values are means + SE of 8 separate experiments. 
* p < 0.05, ** p < 0.01 vs. control (by Dunnett’s test); ## p < 0.01 vs. Ang II 10 M 
(by Student’s t-test). 
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Figure 25  Effects of Ang II and ARB on collagen synthesis in activated HSCs in 
vitro. HSCs were incubated with Ang II in the presence or absence of 10 M 
RNH-6270 (ARB) in serum-free medium for 48 hrs., and collagen synthesis was 
measured by calculating the amount of incorporated [3H]proline, as described in 
Materials and Methods. Values are means + SE of 8 separate experiments. 
Statistical tests were performed with logarithmically transformed values. 
** p < 0.01 vs. control (by Dunnett’s test); ## p < 0.01 vs. Ang II 10 M (by 
Student’s t-test). 
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(Figure 26) 
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Figure 26  Effects of Ang II and ARB on TGF-1 production in activated HSCs 
in vitro. HSCs were incubated with Ang II in the presence or absence of 25 ng/mL 
PDGF (A) and in the presence or absence of 10 M RNH-6270 (ARB) (B) in 
serum-free medium for 48 hrs. The collected culture supernatants were acidified, 
and then total TGF-1 amount in the supernatants was measured as described in 
Materials and Methods. Values are means + SE of 8 separate experiments. (A) 
* p < 0.05, ** p < 0.01 vs. 0 nM Ang II without PDGF, # p < 0.05, ## p < 0.01 vs. 
0 nM Ang II with PDGF, (B) ** p < 0.01 vs. control (by Dunnett’s test); ## p < 0.01 
vs. Ang II 10 M (by Student’s t-test). 
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Figure 27  Effects of Ang II and ARB on mRNA expression of CTGF in activated 
HSCs in vitro. HSCs were incubated with Ang II in the presence or absence of 
10 M RNH-6270 (ARB) in serum-free medium for 48 hrs. Total RNA was 
extracted from cells, and mRNA expression was determined by TaqMan PCR 
analysis as described in Materials and Methods. RNA was normalized to that of 
GAPDH RNA. Values are means + SE of 5 separate experiments. ** p < 0.01 vs. 
control (by Student’s t-test); ## p < 0.01 vs. Ang II 10 M (by Dunnett’s test). 
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